{"meta":{"query_hash":"f341d2f9e313","filters":{"venue":"Clinical Pharmacology in Drug Development"},"cohort_total":57,"direct_labels_cover":0,"predictions_cover":57,"exported":57,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f341d2f9e313","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Pharmacology+in+Drug+Development"},"results":[{"id":"W1904376711","doi":"10.1002/cpdd.27","title":"Impact of Tesamorelin, a Growth Hormone‐Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Adrenal Hormones and Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Ritonavir; Simvastatin; Cmax; Medicine; Pharmacokinetics; Pharmacology; CYP3A; Crossover study; Regimen; Dosing; Internal medicine; Immunology; Placebo; Human immunodeficiency virus (HIV)","score_opus":0.04274883741436251,"score_gpt":0.39492696586806947,"score_spread":0.35217812845370694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1904376711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987601,0.00054626656,0.00017318387,0.00002801341,0.000012491293,0.000054678017,0.000084419094,0.000011901419,0.0003287913],"genre_scores_gemma":[0.9991316,0.00015968466,0.00033005237,0.00004888585,0.00001569915,0.000033525233,0.00008064512,0.0000036262331,0.00019626998],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991903,0.00047666917,0.000051850104,0.00013294604,0.00009251473,0.00005575339],"domain_scores_gemma":[0.99951565,0.00020929005,0.00008991767,0.000053786487,0.000035019366,0.000096279255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011955104,0.00036324226,0.0007470388,0.00014207348,0.00021357922,0.00038682047,0.000137932,0.0005052899,0.00094847486],"category_scores_gemma":[0.001641576,0.00027415523,0.00047302886,0.0001387762,0.00038023505,0.00026070542,0.00015421318,0.00038780575,0.00022673533],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5799965,0.008121439,0.06716172,0.00041020656,0.0010886384,0.00069338514,0.00063401414,0.0012616424,0.24551885,0.0001518163,0.00048678982,0.09447498],"study_design_scores_gemma":[0.02312188,0.50627065,0.40765572,0.000023150544,0.0012870163,0.001621937,0.00026847277,0.0039927433,0.05241422,0.0003075371,0.0029638335,0.00007281554],"about_ca_topic_score_codex":0.00056925614,"about_ca_topic_score_gemma":0.00064807734,"teacher_disagreement_score":0.0011955104,"about_ca_system_score_codex":0.00017383165,"about_ca_system_score_gemma":0.00024350318,"threshold_uncertainty_score":0.006322503},"labels":[],"label_agreement":null},{"id":"W2069868586","doi":"10.1002/cpdd.196","title":"Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients","year":2015,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Covariate; Population; Demographics; Metabolite; Active metabolite; Internal medicine; Pharmacology; Oncology; Demography; Statistics; Environmental health","score_opus":0.15163782514833876,"score_gpt":0.4866974679411927,"score_spread":0.33505964279285394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069868586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89627856,0.0008788824,0.09857796,0.0004953509,0.000017375613,0.00016307404,0.0013779202,0.0001947299,0.0020160314],"genre_scores_gemma":[0.9867801,0.00048175702,0.01034249,0.00010750201,0.000015118422,0.00021037676,0.0009537939,0.000028475988,0.0010802177],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995408,0.00027115116,0.000017316172,0.000081370024,0.000050643335,0.00003880205],"domain_scores_gemma":[0.9991134,0.00058632076,0.00014683086,0.000046325298,0.0000770455,0.000030045143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017151624,0.00040319623,0.00084324356,0.00029838344,0.00014054791,0.00070820167,0.0005267386,0.00051176274,0.00080793235],"category_scores_gemma":[0.0031750663,0.0003235836,0.0011028266,0.00034940196,0.00016866178,0.00036300597,0.00035958234,0.000634101,0.00021969811],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026944703,0.00029066938,0.06255553,0.0001445058,0.0010757349,0.00052682136,0.00030344864,0.8890791,0.0064751147,0.0024329326,0.0013717626,0.033049975],"study_design_scores_gemma":[0.00013883838,0.00090147165,0.016908763,0.0000122584925,0.00030321942,0.00026247583,0.000047544258,0.9759582,0.0012088042,0.002445851,0.0017808427,0.000031697593],"about_ca_topic_score_codex":0.005097721,"about_ca_topic_score_gemma":0.0024539907,"teacher_disagreement_score":0.005097721,"about_ca_system_score_codex":0.00051667745,"about_ca_system_score_gemma":0.00091039995,"threshold_uncertainty_score":0.010136068},"labels":[],"label_agreement":null},{"id":"W2097275353","doi":"10.1002/cpdd.87","title":"Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase‐4 inhibitor","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"","keywords":"Medicine; Dipeptidyl peptidase-4; Dipeptidyl peptidase-4 inhibitor; Pharmacokinetics; Pharmacology; Dipeptidyl peptidase; Population; Diabetes mellitus; Type 2 diabetes; Endocrinology; Biochemistry; Enzyme; Environmental health","score_opus":0.023717635637227237,"score_gpt":0.3603088754721077,"score_spread":0.3365912398348805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097275353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921995,0.00046018575,0.0060403775,0.000026863765,0.000003611226,0.000078428064,0.0007334367,0.000049829807,0.00040771533],"genre_scores_gemma":[0.99568,0.00026006787,0.0024706116,0.00004030717,0.000008684518,0.00008612643,0.0012167778,0.000009324826,0.00022815018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944514,0.00027694507,0.00002585902,0.00010959851,0.00011420269,0.000028224104],"domain_scores_gemma":[0.9992687,0.00036549734,0.00016190397,0.000087790744,0.00007593527,0.000040185678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015042408,0.00028642014,0.0006202727,0.00040873434,0.00012312566,0.0004964465,0.00019763225,0.0002474352,0.0004432626],"category_scores_gemma":[0.0022301134,0.00015982367,0.00051672745,0.00042434625,0.00014071661,0.0001978904,0.00019283898,0.00039635692,0.000104971834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031466145,0.0021284297,0.6874779,0.0004563443,0.0048136376,0.00084007595,0.00073756895,0.038491882,0.07496613,0.0010209981,0.0017870505,0.15581384],"study_design_scores_gemma":[0.0010925094,0.022449015,0.8475371,0.000024733486,0.0022001222,0.0020676535,0.00017959253,0.091428906,0.026196957,0.0013491373,0.0053521227,0.00012212088],"about_ca_topic_score_codex":0.0011044366,"about_ca_topic_score_gemma":0.0005829564,"teacher_disagreement_score":0.0015042408,"about_ca_system_score_codex":0.00039596664,"about_ca_system_score_gemma":0.00048625076,"threshold_uncertainty_score":0.007955313},"labels":[],"label_agreement":null},{"id":"W2123762312","doi":"10.1002/cpdd.35","title":"Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Pfizer; Amgen","keywords":"Medicine; Panitumumab; Irinotecan; Pharmacokinetics; Colorectal cancer; Oncology; Pharmacology; Internal medicine; Cancer; Cetuximab","score_opus":0.029883549016545604,"score_gpt":0.3673054002709479,"score_spread":0.33742185125440227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123762312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720913,0.0018789736,0.00025464137,0.000060376355,0.000017880999,0.000070166956,0.000055365374,0.00002020658,0.00043326034],"genre_scores_gemma":[0.99848795,0.00056313636,0.00044655477,0.00006094245,0.000037408812,0.000036617348,0.00012828298,0.0000068807203,0.0002322395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99944025,0.00025290402,0.000028663124,0.000108711276,0.00011441733,0.00005502152],"domain_scores_gemma":[0.9994504,0.00013685953,0.00019664236,0.0000348646,0.000031214895,0.00015009206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066886103,0.0003468784,0.0012818793,0.00022413624,0.00024314427,0.0004939024,0.0001971809,0.00030544066,0.0006589784],"category_scores_gemma":[0.0016629077,0.00030351058,0.00038283822,0.00037758844,0.00032035235,0.0005834336,0.00017876425,0.0010207186,0.00016064153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2912704,0.01220909,0.14251909,0.0006726598,0.0029687562,0.0017308529,0.0007883777,0.00798707,0.18067203,0.00031189644,0.0019990527,0.3568707],"study_design_scores_gemma":[0.03130577,0.44851246,0.4559142,0.00005749707,0.001801709,0.0051046377,0.00026630072,0.010752244,0.03564757,0.00025324538,0.010296606,0.00008771655],"about_ca_topic_score_codex":0.00068989355,"about_ca_topic_score_gemma":0.0021115527,"teacher_disagreement_score":0.0012818793,"about_ca_system_score_codex":0.0007812492,"about_ca_system_score_gemma":0.0007704763,"threshold_uncertainty_score":0.0056684017},"labels":[],"label_agreement":null},{"id":"W2141030907","doi":"10.1002/cpdd.48","title":"Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers","year":2013,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Pharmacokinetics; Oncology; Internal medicine; Volume of distribution; Response Evaluation Criteria in Solid Tumors; Cancer; Clinical trial; Pharmacology; Phases of clinical research","score_opus":0.05145983826760502,"score_gpt":0.42960602247205204,"score_spread":0.378146184204447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141030907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835545,0.0007260613,0.00038012682,0.00004670592,0.000004059961,0.000014623439,0.00009698129,0.000014922473,0.00036106896],"genre_scores_gemma":[0.9992918,0.00017961451,0.0002351824,0.00003500271,0.0000062527,0.000008266255,0.00014395097,0.000005002766,0.00009494247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99962604,0.00019230695,0.00002711346,0.000067770176,0.000055318207,0.000031431144],"domain_scores_gemma":[0.9990103,0.0005320846,0.00026088848,0.000052013096,0.000039164654,0.000105484505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080058543,0.00018354815,0.000911316,0.0002144847,0.00013560649,0.0005776687,0.00010943405,0.000217317,0.0005999094],"category_scores_gemma":[0.0032594039,0.00014696983,0.00037830236,0.0003882587,0.0002467894,0.00043881644,0.00021382004,0.00050509657,0.000120553035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069121204,0.0009237031,0.7412194,0.0003018946,0.000921939,0.0019872307,0.000628557,0.012845763,0.07152315,0.0004704017,0.0009286335,0.09912808],"study_design_scores_gemma":[0.0011783809,0.018510835,0.94057167,0.000021947428,0.00041538724,0.003769298,0.0001566998,0.020780534,0.011277842,0.000533923,0.0027423038,0.00004110887],"about_ca_topic_score_codex":0.0007058441,"about_ca_topic_score_gemma":0.00097543537,"teacher_disagreement_score":0.000911316,"about_ca_system_score_codex":0.0005849035,"about_ca_system_score_gemma":0.0003528274,"threshold_uncertainty_score":0.004243791},"labels":[],"label_agreement":null},{"id":"W2158520906","doi":"10.1002/cpdd.189","title":"Effect of lapatinib on oral digoxin absorption in patients","year":2015,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"GlaxoSmithKline","keywords":"Lapatinib; Digoxin; Medicine; Pharmacokinetics; Pharmacology; Therapeutic index; Oral administration; Drug interaction; Metastatic breast cancer; Absorption (acoustics); Concomitant; Breast cancer; Drug; Internal medicine; Cancer; Trastuzumab; Heart failure","score_opus":0.03924627127115151,"score_gpt":0.3940237622506233,"score_spread":0.3547774909794718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158520906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959929,0.0018520217,0.00009071004,0.00015521892,0.000011424356,0.000019632582,0.00007781049,0.000009148119,0.0017911881],"genre_scores_gemma":[0.99904615,0.0003222915,0.00008834907,0.00013762413,0.000018567833,0.000007614179,0.00007935042,0.000002528026,0.00029748792],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967647,0.00013828134,0.000024830193,0.000044734814,0.00006610784,0.000049615246],"domain_scores_gemma":[0.9992601,0.00034222906,0.00018180191,0.000031453244,0.000052649066,0.00013179191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004371814,0.00013187664,0.00045677545,0.00009631305,0.00020698496,0.0003256888,0.00009589662,0.00021111038,0.0010924393],"category_scores_gemma":[0.002398364,0.000082763334,0.00028850383,0.00015789628,0.00011829096,0.0002232937,0.00016215046,0.0005264457,0.000124051],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09793171,0.002588508,0.5123551,0.00031018857,0.00088732946,0.002647671,0.0005726596,0.001211661,0.032440137,0.0002150995,0.0021402512,0.34669966],"study_design_scores_gemma":[0.003123806,0.0806368,0.8870918,0.000057489182,0.0008864992,0.0048971428,0.000353927,0.00230965,0.012004422,0.00018262169,0.008420847,0.0000349873],"about_ca_topic_score_codex":0.00075032114,"about_ca_topic_score_gemma":0.00139106,"teacher_disagreement_score":0.0010924393,"about_ca_system_score_codex":0.00041401782,"about_ca_system_score_gemma":0.00028133258,"threshold_uncertainty_score":0.0036545396},"labels":[],"label_agreement":null},{"id":"W2347141072","doi":"10.1002/cpdd.269","title":"Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Pegfilgrastim; Medicine; Biosimilar; Confidence interval; Pharmacodynamics; Pharmacokinetics; Crossover study; Bioequivalence; Clinical endpoint; Internal medicine; Pharmacology; Surrogate endpoint; Filgrastim; Randomized controlled trial; Granulocyte colony-stimulating factor; Placebo; Chemotherapy","score_opus":0.08186570106038771,"score_gpt":0.4648163808401086,"score_spread":0.3829506797797209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2347141072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648833,0.00021615373,0.0023153801,0.000041845287,0.00002902087,0.0005433912,0.00008436399,0.000018039655,0.00026354103],"genre_scores_gemma":[0.99733114,0.00005848431,0.0019995673,0.00011116888,0.0000537855,0.00016657864,0.00014077516,0.0000052366004,0.0001332835],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99609643,0.0023422844,0.00018813292,0.00052672235,0.000682641,0.00016378306],"domain_scores_gemma":[0.9971595,0.0010185085,0.00066648837,0.00049524294,0.0003174404,0.00034285118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0081625655,0.0006311487,0.0006132097,0.00026598925,0.00043587002,0.0006437651,0.00035497267,0.0010527616,0.001196852],"category_scores_gemma":[0.007943275,0.00034683725,0.0006095945,0.00018346748,0.0009342729,0.00040396012,0.00037317644,0.0011427983,0.00036289144],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16661768,0.04195549,0.040400144,0.0006808213,0.0007808734,0.00091039174,0.002278327,0.002291273,0.6760379,0.0012498158,0.0009830388,0.065814346],"study_design_scores_gemma":[0.02247225,0.8003203,0.09288099,0.000029799192,0.0005595376,0.0021773076,0.00020258213,0.006017556,0.071608424,0.0005074701,0.0031650846,0.000058664904],"about_ca_topic_score_codex":0.00019602483,"about_ca_topic_score_gemma":0.00015816482,"teacher_disagreement_score":0.0081625655,"about_ca_system_score_codex":0.0002595138,"about_ca_system_score_gemma":0.0004990862,"threshold_uncertainty_score":0.043168306},"labels":[],"label_agreement":null},{"id":"W2531615040","doi":"10.1002/cpdd.319","title":"Comparison of the Pharmacokinetics of Ketorolac Tromethamine After Continuous Subcutaneous Infusion and Repeat Intramuscular Bolus Injections in Healthy Adult Subjects","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacological Receptor Mechanisms and Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"","keywords":"Medicine; Ketorolac Tromethamine; Pharmacokinetics; Anesthesia; Bolus (digestion); Cmax; Crossover study; Intramuscular injection; Ketorolac; Bioavailability; Regimen; Analgesic; Pharmacology; Surgery; Placebo","score_opus":0.017526939900527116,"score_gpt":0.35658175209653215,"score_spread":0.33905481219600503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531615040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991648,0.00029334554,0.00023843821,0.000006903341,0.0000078837875,0.00007689099,0.00006964319,0.000014152016,0.00012794911],"genre_scores_gemma":[0.9987105,0.00015510723,0.0005055152,0.0000390183,0.000025296036,0.00010583519,0.00014799631,0.000005339172,0.00030553047],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996333,0.00012728092,0.000027373782,0.00008591904,0.000083804116,0.00004223878],"domain_scores_gemma":[0.9992405,0.000210862,0.00021756669,0.00005778352,0.00008710925,0.00018628288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006723717,0.00041621705,0.00081429293,0.00021195447,0.00019100192,0.00033309453,0.00015147924,0.0004933627,0.0010523705],"category_scores_gemma":[0.0015873022,0.00031638562,0.00022011115,0.00018238035,0.00030215012,0.00030423483,0.0000948597,0.00043584345,0.000330803],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5054813,0.015096823,0.13586192,0.0004136264,0.0006745466,0.0007111089,0.0010744041,0.00087956694,0.25445068,0.000096981465,0.0006139872,0.08464513],"study_design_scores_gemma":[0.013710305,0.38312957,0.5790662,0.000018764524,0.00051082403,0.0009344129,0.00023267207,0.0032251978,0.018233579,0.000048694594,0.00083384843,0.000055911427],"about_ca_topic_score_codex":0.0006937542,"about_ca_topic_score_gemma":0.00052225916,"teacher_disagreement_score":0.0010523705,"about_ca_system_score_codex":0.00017585086,"about_ca_system_score_gemma":0.00021755169,"threshold_uncertainty_score":0.003555894},"labels":[],"label_agreement":null},{"id":"W2606334551","doi":"10.1002/cpdd.358","title":"Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Merck","keywords":"Raltegravir; Pharmacokinetics; Bioavailability; Pharmacology; Medicine; Biopharmaceutics; Dosing; Biopharmaceutics Classification System; In vivo; Human immunodeficiency virus (HIV); Chemistry; Virology; Antiretroviral therapy; In vitro; Biological activity; Biology; Viral load; Biochemistry; Pharmacognosy; Biotechnology","score_opus":0.08495309511939617,"score_gpt":0.41743036901476527,"score_spread":0.3324772738953691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606334551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629873,0.00094958965,0.0017986214,0.000032772572,0.000029620942,0.000091288704,0.0002074052,0.00008208108,0.0005100318],"genre_scores_gemma":[0.99543047,0.00038931248,0.002753507,0.000042972533,0.00002061247,0.0000988826,0.0003757913,0.0000295099,0.00085891],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999713,0.00009372795,0.000015655358,0.000056046938,0.0000978808,0.000023729528],"domain_scores_gemma":[0.99969375,0.00008699556,0.000064497806,0.000040875344,0.00004450478,0.00006944263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005575608,0.00020206757,0.0007429885,0.00021335226,0.00011636099,0.00038794943,0.00025542374,0.00033417155,0.0012595322],"category_scores_gemma":[0.001021953,0.00022395723,0.0002673597,0.00017809172,0.0001557866,0.00043068884,0.0000872899,0.0008350306,0.00025539135],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032740235,0.0042536864,0.004773112,0.00019538576,0.00017938875,0.00014238156,0.00021794385,0.0015386135,0.82584304,0.0002561077,0.00090750196,0.12895271],"study_design_scores_gemma":[0.008979698,0.20152168,0.15101346,0.0000619421,0.0005019543,0.0029295352,0.00016884223,0.042289842,0.58010924,0.00051334006,0.0117408205,0.00016969602],"about_ca_topic_score_codex":0.0005040284,"about_ca_topic_score_gemma":0.00048667577,"teacher_disagreement_score":0.0012595322,"about_ca_system_score_codex":0.00025184482,"about_ca_system_score_gemma":0.00030831102,"threshold_uncertainty_score":0.0042135715},"labels":[],"label_agreement":null},{"id":"W2761677898","doi":"10.1002/cpdd.394","title":"Categorization of Abuse Potential–Related Adverse Events","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Categorization; Adverse effect; Medical emergency; Pharmacology; Artificial intelligence","score_opus":0.13228444398396244,"score_gpt":0.5026786822963262,"score_spread":0.37039423831236373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761677898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79958344,0.018166758,0.08096488,0.0026666264,0.0007482588,0.02063377,0.018670699,0.0012368927,0.057328638],"genre_scores_gemma":[0.8164594,0.0057741627,0.15275653,0.0012297326,0.000265005,0.0034515818,0.015232043,0.00014968512,0.0046818894],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.991823,0.0019684378,0.0028094677,0.0003619548,0.0026768504,0.00036032384],"domain_scores_gemma":[0.9842455,0.0040091276,0.0040454683,0.0010332913,0.0062106634,0.00045601168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006369513,0.00067256304,0.0010050945,0.007816344,0.00081140106,0.0011754155,0.001017358,0.0006177786,0.003038819],"category_scores_gemma":[0.014435649,0.00015640682,0.001282631,0.003034035,0.00047947225,0.0009703388,0.0012914774,0.0008085469,0.00072204496],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002881922,0.00074300164,0.536884,0.005865731,0.000589082,0.0047172653,0.0027783134,0.0035631238,0.025272219,0.0058389627,0.015342989,0.3955233],"study_design_scores_gemma":[0.0002558334,0.0027799031,0.8526664,0.002110005,0.00063488894,0.0133690685,0.0032780406,0.014566303,0.015141988,0.0118305655,0.08309729,0.0002697214],"about_ca_topic_score_codex":0.0025391479,"about_ca_topic_score_gemma":0.003153119,"teacher_disagreement_score":0.007816344,"about_ca_system_score_codex":0.0009140443,"about_ca_system_score_gemma":0.0021536753,"threshold_uncertainty_score":0.033685625},"labels":[],"label_agreement":null},{"id":"W2766447985","doi":"10.1002/cpdd.395","title":"Pharmacokinetics of the BCL‐2 Inhibitor Venetoclax in Healthy Chinese Subjects","year":2017,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genentech; AbbVie","keywords":"Venetoclax; Medicine; Pharmacokinetics; Pharmacology; Internal medicine; Oncology; Leukemia","score_opus":0.056235550579271334,"score_gpt":0.45602244500090494,"score_spread":0.3997868944216336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766447985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994849,0.00014165633,0.00012269158,0.000011401586,0.0000022040276,0.000021908494,0.00004952671,0.0000066937546,0.0001590484],"genre_scores_gemma":[0.9992624,0.000070319344,0.00016416328,0.000047051108,0.0000065481577,0.000033198263,0.000094944655,0.0000019710453,0.00031941797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998266,0.000065360065,0.000008763706,0.00003827625,0.000032060863,0.000028902543],"domain_scores_gemma":[0.99978036,0.00006658473,0.000039785195,0.000023845032,0.000030886444,0.00005852453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049850426,0.00027759155,0.00037183607,0.00021104902,0.00037079392,0.00020025639,0.000107290114,0.00023813153,0.00079010875],"category_scores_gemma":[0.0007111422,0.00017758811,0.00015845148,0.00020469166,0.0002812594,0.00020693426,0.000113561044,0.00028815912,0.00015927052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0616911,0.0038636932,0.63058066,0.00022623538,0.0006694531,0.0012097335,0.0021242746,0.002522107,0.2189191,0.00029366685,0.0014562831,0.07644368],"study_design_scores_gemma":[0.0021814548,0.036954425,0.93772686,0.0000084252015,0.00043211225,0.000951041,0.00037479834,0.0044457205,0.014916526,0.00012229398,0.0018432473,0.000043085656],"about_ca_topic_score_codex":0.0045776,"about_ca_topic_score_gemma":0.0026343737,"teacher_disagreement_score":0.0045776,"about_ca_system_score_codex":0.00037705086,"about_ca_system_score_gemma":0.00042020532,"threshold_uncertainty_score":0.009101927},"labels":[],"label_agreement":null},{"id":"W2793257861","doi":"10.1002/cpdd.439","title":"Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Tolerability; Pharmacokinetics; Nonsteroidal; Atopic dermatitis; Incidence (geometry); Cohort; Adverse effect; Safety profile; Open label; Pharmacology; Dermatology; Internal medicine","score_opus":0.044324968753877196,"score_gpt":0.42396579361689907,"score_spread":0.37964082486302186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793257861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513704,0.0009341231,0.00091188005,0.00012652788,0.000033599277,0.001151592,0.0009865009,0.00006227615,0.0006564397],"genre_scores_gemma":[0.9935154,0.00084153167,0.0015270888,0.00039040772,0.000108684566,0.0008766641,0.0015344055,0.000039149134,0.0011666731],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992945,0.00031268015,0.00003995064,0.00013194006,0.00011764485,0.00010327906],"domain_scores_gemma":[0.99871373,0.00030986525,0.00029963418,0.00015898616,0.00018915274,0.0003286372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023157948,0.0011937722,0.0017828505,0.00023697392,0.000501314,0.00074382516,0.0005541684,0.00095141045,0.0029947003],"category_scores_gemma":[0.0016591824,0.0005184287,0.0010336349,0.00023470218,0.0006080261,0.0009772163,0.00020556024,0.00207774,0.0006906297],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4230447,0.13262716,0.019214196,0.0011978323,0.0018249133,0.00064460916,0.00063646794,0.0024873116,0.30302405,0.00020091898,0.0049265916,0.11017128],"study_design_scores_gemma":[0.081468575,0.8403945,0.048960984,0.000032831034,0.0009897861,0.0007183795,0.00014205267,0.0013599524,0.022770276,0.00017620974,0.0029257282,0.00006063232],"about_ca_topic_score_codex":0.0005879407,"about_ca_topic_score_gemma":0.0010030427,"teacher_disagreement_score":0.0029947003,"about_ca_system_score_codex":0.0005059036,"about_ca_system_score_gemma":0.0010459024,"threshold_uncertainty_score":0.012247205},"labels":[],"label_agreement":null},{"id":"W2793645751","doi":"10.1002/cpdd.433","title":"Pharmacokinetic Drug Interaction Study of Bazedoxifene and Ibuprofen","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Pfizer","keywords":"Pharmacokinetics; Ibuprofen; Medicine; Bioequivalence; Crossover study; Pharmacology; Confidence interval; Internal medicine; Urology; Placebo; Pathology","score_opus":0.02197730178811429,"score_gpt":0.38759583798265373,"score_spread":0.36561853619453943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793645751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626154,0.0018951497,0.0011357936,0.00006757261,0.00003558939,0.00014103233,0.00008360903,0.000022210397,0.00035748057],"genre_scores_gemma":[0.9980502,0.00046082007,0.00074531994,0.00006808258,0.000043928965,0.00006582549,0.000101547004,0.0000059269105,0.00045834985],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.998643,0.0007776426,0.000056654142,0.00012203113,0.00032467148,0.00007609027],"domain_scores_gemma":[0.9987937,0.0006044779,0.0002746461,0.000070130765,0.00010196144,0.00015508689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013395746,0.00040206723,0.0014824459,0.00036273253,0.00029822788,0.0005076269,0.00022304346,0.00060946844,0.0021138538],"category_scores_gemma":[0.0037781333,0.00031978017,0.00088052655,0.00032534462,0.00028158777,0.00031041514,0.0002088122,0.0006772943,0.00028095653],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34374082,0.013971935,0.11322744,0.0010513448,0.0071520046,0.0016792207,0.00066291104,0.0030099666,0.41910824,0.00051195326,0.00086280593,0.09502138],"study_design_scores_gemma":[0.03531351,0.40128103,0.34533337,0.00006704066,0.008877855,0.006271959,0.00044390294,0.02496563,0.16273774,0.00064427237,0.013902295,0.00016150199],"about_ca_topic_score_codex":0.0012891871,"about_ca_topic_score_gemma":0.0008000905,"teacher_disagreement_score":0.0021138538,"about_ca_system_score_codex":0.00038297474,"about_ca_system_score_gemma":0.0004996703,"threshold_uncertainty_score":0.0070844293},"labels":[],"label_agreement":null},{"id":"W2800574556","doi":"10.1002/cpdd.458","title":"A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Pfizer","keywords":"Atorvastatin; Cmax; Medicine; Pharmacokinetics; Pharmacology; Dosing; Urology; Internal medicine","score_opus":0.04281427300583475,"score_gpt":0.40654031695031073,"score_spread":0.363726043944476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800574556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871194,0.0008516169,0.00016533036,0.000020226458,0.000009242225,0.000065598884,0.00004877378,0.0000039196907,0.00012339526],"genre_scores_gemma":[0.99873656,0.00038316028,0.00033975142,0.0000560546,0.00003364038,0.0000887199,0.000085790656,0.0000023394048,0.00027398477],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99937683,0.00032409801,0.000031285133,0.000083147665,0.00013170364,0.000053002892],"domain_scores_gemma":[0.99935335,0.000272406,0.00014177148,0.00004603164,0.000045425808,0.00014102683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014751864,0.00052245334,0.0011119922,0.0002528276,0.00047728143,0.00035753788,0.00022835923,0.00071215647,0.0010920417],"category_scores_gemma":[0.0017079113,0.00046148754,0.00068373623,0.00025786378,0.00035748727,0.00027341052,0.00018827828,0.0004965426,0.00018360224],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51201147,0.0139478315,0.23940928,0.00089308165,0.0028786936,0.0009972228,0.0007721249,0.00062850316,0.17795368,0.00012644201,0.0003174847,0.05006421],"study_design_scores_gemma":[0.019521642,0.3506005,0.61002547,0.000022803593,0.002348818,0.0009919283,0.00027093408,0.0016777873,0.012027473,0.00012961158,0.002326715,0.00005627368],"about_ca_topic_score_codex":0.0012892288,"about_ca_topic_score_gemma":0.0019256247,"teacher_disagreement_score":0.0014751864,"about_ca_system_score_codex":0.0002786073,"about_ca_system_score_gemma":0.00048603688,"threshold_uncertainty_score":0.0078015924},"labels":[],"label_agreement":null},{"id":"W2803358008","doi":"10.1002/cpdd.473","title":"Tramadol Hydrochloride at Steady State Lacks Clinically Relevant QTc Interval Increases in Healthy Adults","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Tata Consultancy Services; Janssen Research and Development; Janssen Scientific Affairs; Valeant Pharmaceuticals International","keywords":"Medicine; Placebo; Tramadol; QT interval; Anesthesia; Moxifloxacin; Adverse effect; Tramadol Hydrochloride; Crossover study; Nausea; Internal medicine; Analgesic; Antibiotics","score_opus":0.0815724810782293,"score_gpt":0.4292402465489839,"score_spread":0.3476677654707546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803358008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962852,0.0028698072,0.00016798054,0.00006946625,0.000035982914,0.0001314903,0.000079446676,0.000014491872,0.00034616777],"genre_scores_gemma":[0.9978269,0.0010947613,0.00039128348,0.00022347966,0.000090226196,0.00008367103,0.00010445672,0.000002695908,0.00018242958],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994735,0.00021584978,0.000063306245,0.0000935554,0.000097419346,0.000056361183],"domain_scores_gemma":[0.9991235,0.0002739127,0.00029878135,0.000055650118,0.0000612323,0.000186874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009924023,0.00042013606,0.0010212205,0.00019519932,0.0002938179,0.00032092826,0.00029477468,0.0007372115,0.0013981103],"category_scores_gemma":[0.001738996,0.0003809166,0.00044500607,0.00017091238,0.00037999553,0.0004923963,0.00020042583,0.00073370396,0.0002364174],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44048214,0.022575004,0.10379678,0.0024864937,0.002092553,0.0013122997,0.0007683345,0.0007015431,0.21282135,0.00023448763,0.001293651,0.21143532],"study_design_scores_gemma":[0.073210225,0.54887116,0.3670666,0.000080081816,0.0012110361,0.0013952944,0.00016133387,0.000706635,0.0054369965,0.0001308549,0.0016886204,0.00004110133],"about_ca_topic_score_codex":0.00050904584,"about_ca_topic_score_gemma":0.0012747543,"teacher_disagreement_score":0.0013981103,"about_ca_system_score_codex":0.00016660543,"about_ca_system_score_gemma":0.00032030744,"threshold_uncertainty_score":0.005248368},"labels":[],"label_agreement":null},{"id":"W2806608475","doi":"10.1002/cpdd.581","title":"Pharmacokinetics of Perampanel in Healthy Korean, White, and Japanese Adult Subjects","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Perampanel; Pharmacokinetics; White (mutation); Pharmacology; Adverse effect; Genetics","score_opus":0.050979633929201226,"score_gpt":0.4227265915702705,"score_spread":0.37174695764106924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806608475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867755,0.00044862225,0.00017363392,0.000014536817,0.0000046103874,0.000025794672,0.00012660344,0.000008960837,0.0005197181],"genre_scores_gemma":[0.9985825,0.00030212777,0.0002049499,0.00008847059,0.0000075499497,0.00003426524,0.00022705062,0.0000038546004,0.0005493528],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999013,0.000020557363,0.000010117865,0.000031070136,0.000016644608,0.000020205365],"domain_scores_gemma":[0.9998282,0.000028049495,0.00004397173,0.000014955393,0.000028913177,0.0000557834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027429799,0.00030333642,0.00037214317,0.0001907675,0.00023311963,0.00021095063,0.00008139698,0.00018793393,0.0007799865],"category_scores_gemma":[0.0004990094,0.00018782626,0.00014096749,0.0002256531,0.00016362485,0.00029782072,0.00010637205,0.00021573005,0.00023713305],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036468547,0.0033200912,0.74836624,0.00038721596,0.00083775906,0.0021850532,0.003930443,0.0009834127,0.12770616,0.00040012976,0.001815634,0.07359924],"study_design_scores_gemma":[0.0005891115,0.012612052,0.97947115,0.000007811022,0.00028603556,0.0017230208,0.00055874453,0.00089860783,0.0019964788,0.00008885924,0.0017387485,0.000029444074],"about_ca_topic_score_codex":0.0023163224,"about_ca_topic_score_gemma":0.002110026,"teacher_disagreement_score":0.0023163224,"about_ca_system_score_codex":0.00015998665,"about_ca_system_score_gemma":0.00012900207,"threshold_uncertainty_score":0.004605651},"labels":[],"label_agreement":null},{"id":"W2807342171","doi":"10.1002/cpdd.471","title":"Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Pfizer","keywords":"Janus kinase inhibitor; Medicine; Tofacitinib; Dosing; Pharmacokinetics; Psoriasis; Volume of distribution; Renal function; Plaque psoriasis; Internal medicine; Body surface area; Creatinine; Body mass index; Clearance; Gastroenterology; Pharmacology; Urology; Immunology; Rheumatoid arthritis","score_opus":0.01935625667845373,"score_gpt":0.303296412492652,"score_spread":0.28394015581419824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807342171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978248,0.00075061567,0.00064935285,0.000038104394,0.0000033702477,0.000019574883,0.00029758704,0.000014813823,0.00040185056],"genre_scores_gemma":[0.99914587,0.00018669666,0.00025284692,0.00003600624,0.000010156405,0.000011228528,0.00025924915,0.000002107367,0.000095912124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976355,0.00007768705,0.000025873971,0.000053471493,0.000055433557,0.000023984892],"domain_scores_gemma":[0.99936086,0.00031009532,0.0001758443,0.00004166273,0.00004612985,0.00006539433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061542494,0.00021646355,0.0005757896,0.00021865487,0.00015777364,0.0003443727,0.00008373477,0.00026731123,0.0007625463],"category_scores_gemma":[0.002013792,0.00013282796,0.000382193,0.0003048338,0.000088744324,0.00027301745,0.00010699301,0.00035953228,0.00017359562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007788235,0.00049150357,0.9158036,0.00012765093,0.00061587803,0.0009999147,0.00030042074,0.0057838843,0.009661449,0.00018872062,0.0011104655,0.057128217],"study_design_scores_gemma":[0.00054839556,0.0046603866,0.9742508,0.000024475787,0.00031953343,0.0036017224,0.0001568921,0.01239374,0.0012097204,0.00037539523,0.002431222,0.000027681004],"about_ca_topic_score_codex":0.0010117206,"about_ca_topic_score_gemma":0.00087204674,"teacher_disagreement_score":0.0010117206,"about_ca_system_score_codex":0.00026241838,"about_ca_system_score_gemma":0.00025429117,"threshold_uncertainty_score":0.003254652},"labels":[],"label_agreement":null},{"id":"W2888696165","doi":"10.1002/cpdd.607","title":"Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Pfizer","keywords":"Medicine; Pharmacokinetics; Renal function; Selective estrogen receptor modulator; Placebo; Internal medicine; Osteoporosis; Impaired renal function; Postmenopausal women; Urology; Estrogen receptor; Cancer","score_opus":0.008928351467708354,"score_gpt":0.3344801991064224,"score_spread":0.32555184763871403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888696165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981192,0.0013014841,0.00014892267,0.000018664066,0.0000042117103,0.00001663833,0.00007565027,0.0000059034005,0.0003093198],"genre_scores_gemma":[0.9992767,0.0002944289,0.00012357012,0.000029088507,0.000008922615,0.000012477723,0.000048320053,0.0000017485559,0.00020478379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996612,0.00018290791,0.000016131631,0.00003546572,0.00007986206,0.000024513194],"domain_scores_gemma":[0.99945337,0.0002011778,0.0001686435,0.00004191468,0.000056453868,0.00007842718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007765172,0.00020199342,0.00041279005,0.00021292917,0.00017622046,0.000242246,0.000085135085,0.00027960038,0.0006013726],"category_scores_gemma":[0.0016984377,0.00019780794,0.00021603303,0.00017564103,0.00014501704,0.00018773512,0.00013759742,0.00024082306,0.00011764841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051072232,0.0010748901,0.7993885,0.00018050196,0.00058574986,0.00045903062,0.0004917207,0.00048916053,0.10574067,0.0000861929,0.00027036836,0.040160954],"study_design_scores_gemma":[0.00034110845,0.011127182,0.9808142,0.000006016247,0.0002405589,0.0005108601,0.000090246416,0.00061110826,0.0054626223,0.00003994545,0.0007454392,0.000010627012],"about_ca_topic_score_codex":0.001081128,"about_ca_topic_score_gemma":0.0012342505,"teacher_disagreement_score":0.001081128,"about_ca_system_score_codex":0.00012365276,"about_ca_system_score_gemma":0.00017429769,"threshold_uncertainty_score":0.004106641},"labels":[],"label_agreement":null},{"id":"W2889013879","doi":"10.1002/cpdd.608","title":"Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Levothyroxine; Bioequivalence; Medicine; Bioavailability; Pharmacokinetics; Crossover study; Randomization; Capsule; Oral administration; Dosage form; Pharmacology; Internal medicine; Randomized controlled trial; Placebo; Hormone","score_opus":0.2020510462544798,"score_gpt":0.4820193330155821,"score_spread":0.2799682867611023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889013879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973929,0.00095848326,0.0010698007,0.000018515004,0.000022245546,0.00012061387,0.00008016707,0.000018523426,0.000318779],"genre_scores_gemma":[0.9973169,0.00033642654,0.0013342855,0.000030007255,0.000029576398,0.000098761244,0.0001516506,0.000008055098,0.0006943237],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994611,0.00023857807,0.000034670473,0.000066707595,0.00015836065,0.000040557206],"domain_scores_gemma":[0.9993542,0.0002658892,0.00013700032,0.00006791775,0.000062518884,0.00011242373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075049384,0.00030987756,0.00067493203,0.00023906697,0.00010184385,0.00040298913,0.00021441864,0.00033404856,0.001355982],"category_scores_gemma":[0.0013019262,0.0002043533,0.00026039913,0.00020935942,0.00036476806,0.00038658787,0.00014937477,0.0006147426,0.00026558328],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12374737,0.004624088,0.0036538716,0.00039953948,0.0003937494,0.00014074583,0.00025957255,0.0009376503,0.7842141,0.00025583108,0.000316315,0.0810572],"study_design_scores_gemma":[0.012425426,0.60423,0.07181733,0.000044850298,0.0007147013,0.0004632091,0.00021534447,0.0087792985,0.2973059,0.00019601689,0.00372021,0.00008778992],"about_ca_topic_score_codex":0.00050891005,"about_ca_topic_score_gemma":0.00032164194,"teacher_disagreement_score":0.001355982,"about_ca_system_score_codex":0.00018214088,"about_ca_system_score_gemma":0.00029485422,"threshold_uncertainty_score":0.0045362115},"labels":[],"label_agreement":null},{"id":"W2906348647","doi":"10.1002/cpdd.643","title":"Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With <i>BRAF</i> <sup>V600</sup> Mutation–Positive Metastatic Malignancy","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Vemurafenib; Medicine; Pharmacokinetics; Pharmacology; Area under the curve; Dosing; Rifampicin; Confidence interval; Internal medicine; Gastroenterology; Urology; Metastatic melanoma; Cancer; Pathology; Tuberculosis","score_opus":0.01646367025858358,"score_gpt":0.3114050173212828,"score_spread":0.2949413470626992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906348647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893767,0.00051573577,0.0001596791,0.00007364095,0.00001595729,0.000026799511,0.000036035282,0.000017729011,0.00021672636],"genre_scores_gemma":[0.9996227,0.00007683406,0.00012304154,0.000035348574,0.000018953253,0.00001093544,0.00004503757,0.0000027184399,0.000064484855],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957603,0.00022048218,0.000026206175,0.00007475661,0.000053200445,0.00004938378],"domain_scores_gemma":[0.99889165,0.00036502507,0.00031516564,0.00006704398,0.00005636717,0.00030477732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008033128,0.0003819535,0.00094792334,0.00015479318,0.00021860194,0.00039160904,0.00015524446,0.00030553792,0.0007084764],"category_scores_gemma":[0.0021504406,0.00022466235,0.0006276608,0.000119497236,0.0002755493,0.0002946853,0.00014848947,0.0009873478,0.00015502301],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39846098,0.012821134,0.16728286,0.00028441285,0.0019853476,0.001331119,0.0005591789,0.006161936,0.19928584,0.00016371052,0.0024079257,0.20925556],"study_design_scores_gemma":[0.030912649,0.4417844,0.47458845,0.000045715118,0.0010278804,0.0027740872,0.00022581569,0.010360552,0.035070185,0.00018789031,0.0029430173,0.00007940912],"about_ca_topic_score_codex":0.0004279701,"about_ca_topic_score_gemma":0.0006842672,"teacher_disagreement_score":0.00094792334,"about_ca_system_score_codex":0.0004569795,"about_ca_system_score_gemma":0.00036549472,"threshold_uncertainty_score":0.004248321},"labels":[],"label_agreement":null},{"id":"W2937154946","doi":"10.1002/cpdd.685","title":"Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Pharmacology; Metformin; Pharmacokinetic interaction; Drug interaction; Internal medicine","score_opus":0.05189335607255027,"score_gpt":0.4140086072678435,"score_spread":0.3621152511952932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937154946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988386,0.0002846734,0.00029612475,0.000014131107,0.000018863671,0.00015643702,0.00011562101,0.000015895168,0.0002596694],"genre_scores_gemma":[0.99864775,0.00009235822,0.0005582184,0.000054079926,0.00002507868,0.00011407001,0.00013865059,0.0000052528026,0.00036452414],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991074,0.00040166528,0.00004458638,0.00022027965,0.00016616007,0.000059877722],"domain_scores_gemma":[0.99905425,0.00024675424,0.00024335671,0.00009751797,0.00013338332,0.00022481674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015710696,0.00063641684,0.00094206474,0.0002527324,0.00044867172,0.00042799197,0.00022710834,0.00064603577,0.0012077402],"category_scores_gemma":[0.0026914736,0.00040478585,0.00046603507,0.00021855526,0.0002864272,0.00047551922,0.00027660665,0.00065198395,0.0003111867],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48483726,0.019929394,0.23883569,0.00045558988,0.0012284655,0.0006979828,0.0009524771,0.0013134384,0.1593231,0.00011916413,0.0009674478,0.09133999],"study_design_scores_gemma":[0.011424259,0.4018269,0.55223286,0.000029271856,0.0010765819,0.0011192381,0.00034351228,0.0049640695,0.02458481,0.000106618565,0.0022124003,0.00007947374],"about_ca_topic_score_codex":0.0006108715,"about_ca_topic_score_gemma":0.0006214808,"teacher_disagreement_score":0.0015710696,"about_ca_system_score_codex":0.00027072374,"about_ca_system_score_gemma":0.0003453556,"threshold_uncertainty_score":0.008308709},"labels":[],"label_agreement":null},{"id":"W2945178990","doi":"10.1002/cpdd.699","title":"Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Methadone; Medicine; Pharmacokinetics; Dosing; Confidence interval; Pharmacology; Drug interaction; Methadone maintenance; Internal medicine","score_opus":0.08319404251493585,"score_gpt":0.4393486597931239,"score_spread":0.35615461727818803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945178990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765354,0.00068935804,0.0010293052,0.00002480799,0.0000069353237,0.00008532014,0.000106359985,0.00001527825,0.00038912366],"genre_scores_gemma":[0.9982064,0.00021417755,0.0011135152,0.000039018876,0.000010222829,0.000040231873,0.00010396206,0.0000062586682,0.00026628657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979346,0.0010943793,0.000061427505,0.00021697505,0.0006228869,0.000069832684],"domain_scores_gemma":[0.997973,0.00090264506,0.00061475794,0.00010696642,0.0002629476,0.00013968785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022050722,0.00032867672,0.000585177,0.00020696384,0.00015900451,0.00048255708,0.00025217375,0.000359773,0.0007998263],"category_scores_gemma":[0.0048796786,0.00024107896,0.00043373505,0.00017445016,0.00015810844,0.0002982509,0.00020521988,0.00048529226,0.00011920168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066466354,0.007032078,0.38209638,0.0008648501,0.004197658,0.00073914154,0.00094525475,0.006123679,0.3537882,0.00046258906,0.00088444,0.1763994],"study_design_scores_gemma":[0.0028070165,0.13857657,0.7119,0.00005930909,0.0016379381,0.003058347,0.00040533848,0.045573965,0.09136352,0.00024160993,0.004261762,0.00011470437],"about_ca_topic_score_codex":0.00091812667,"about_ca_topic_score_gemma":0.0012586381,"teacher_disagreement_score":0.0022050722,"about_ca_system_score_codex":0.00039576303,"about_ca_system_score_gemma":0.00041130235,"threshold_uncertainty_score":0.011661708},"labels":[],"label_agreement":null},{"id":"W2953947897","doi":"10.1002/cpdd.720","title":"A First‐in‐Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Medicinal Plants and Neuroprotection","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Dosing; Placebo; Randomized controlled trial; Erythema; Single Center; Anesthesia; Internal medicine; Surgery; Pathology","score_opus":0.06716203326062947,"score_gpt":0.42181957715298724,"score_spread":0.35465754389235776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953947897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642772,0.0022924368,0.002594943,0.00060232583,0.00054120115,0.025371583,0.0017403115,0.00020824153,0.002371765],"genre_scores_gemma":[0.95162797,0.002464871,0.0066666137,0.0024120528,0.0008500001,0.024334874,0.0013208862,0.00006378291,0.010258949],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993037,0.00027947983,0.000046426434,0.0001515371,0.00007365578,0.0001451574],"domain_scores_gemma":[0.99914277,0.00019078873,0.0001508417,0.00011576514,0.0001122488,0.00028772547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022475915,0.0023481303,0.0035694607,0.0005880279,0.0010475896,0.0008870943,0.0008081206,0.0020552324,0.0070058554],"category_scores_gemma":[0.0014746668,0.0012957408,0.0012939051,0.0003633446,0.0013775325,0.0012418773,0.00045736303,0.002389169,0.0013728335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8886806,0.06928272,0.0010229687,0.0006050927,0.00053642,0.00011817457,0.00015879955,0.0002950902,0.018500907,0.0001508374,0.0014689843,0.019179478],"study_design_scores_gemma":[0.50224864,0.49165338,0.0026226013,0.000015363155,0.00026398816,0.00004286473,0.00003601104,0.0002333908,0.0012828645,0.0001685198,0.0014067941,0.000025619805],"about_ca_topic_score_codex":0.00065380125,"about_ca_topic_score_gemma":0.0020685398,"teacher_disagreement_score":0.0070058554,"about_ca_system_score_codex":0.0005069335,"about_ca_system_score_gemma":0.0017594753,"threshold_uncertainty_score":0.023436844},"labels":[],"label_agreement":null},{"id":"W2981182356","doi":"10.1002/cpdd.747","title":"A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV‐0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Biohaven Pharmaceuticals","keywords":"Bioequivalence; Riluzole; Medicine; Pharmacokinetics; Geometric mean; Confidence interval; Adverse effect; Area under the curve; Sublingual administration; Pharmacology; Internal medicine; Amyotrophic lateral sclerosis; Mathematics","score_opus":0.08764181574720296,"score_gpt":0.4492870065205536,"score_spread":0.3616451907733506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981182356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989587,0.00027299006,0.00041972156,0.000010589486,0.000011327949,0.00011451783,0.000063322834,0.00001145772,0.00013740487],"genre_scores_gemma":[0.99880695,0.00014302376,0.00052298687,0.00004002826,0.000016852051,0.00010128574,0.00011185828,0.0000048795146,0.00025209214],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999134,0.00045909907,0.000045513658,0.0001690104,0.00013060198,0.000061754414],"domain_scores_gemma":[0.9995291,0.00012270005,0.000108139175,0.000074398784,0.00006543092,0.00010016798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016538666,0.0005414562,0.00084372575,0.00021673575,0.0002573355,0.00041074888,0.00022601182,0.0007426537,0.0010581244],"category_scores_gemma":[0.0014113272,0.0003173596,0.0004352906,0.00019642017,0.00045098807,0.00037336646,0.00019214816,0.00055865454,0.00032872372],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36395678,0.017670386,0.03582193,0.00054326275,0.0016070835,0.00035759536,0.0019322449,0.0016426976,0.4739794,0.0005380633,0.0009864131,0.10096402],"study_design_scores_gemma":[0.028915308,0.61984503,0.28467336,0.00003547118,0.0012716475,0.0009926152,0.0005881396,0.009818471,0.049907543,0.0002702368,0.003544582,0.00013764181],"about_ca_topic_score_codex":0.0013215049,"about_ca_topic_score_gemma":0.0007761202,"teacher_disagreement_score":0.0016538666,"about_ca_system_score_codex":0.00027661165,"about_ca_system_score_gemma":0.00036695233,"threshold_uncertainty_score":0.008746564},"labels":[],"label_agreement":null},{"id":"W2992701293","doi":"10.1002/cpdd.753","title":"Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency","year":2019,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Montreal Clinical Research Institute; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Dosing; Primary immunodeficiency; Pharmacokinetics; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.013220766930134178,"score_gpt":0.2940168658577188,"score_spread":0.2807960989275846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992701293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977539,0.00081459805,0.00076202076,0.00005260225,0.00000879138,0.000034601882,0.00010172251,0.000025580679,0.0004461267],"genre_scores_gemma":[0.99940956,0.00008535311,0.0002565872,0.000042407988,0.000009520923,0.000019813619,0.000075479096,0.0000029172681,0.000098371034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925286,0.00036592715,0.00003957414,0.00012748256,0.00015851365,0.00005561944],"domain_scores_gemma":[0.9982322,0.00081964064,0.00045010174,0.00012913572,0.000082924846,0.00028606932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013240675,0.00026942368,0.000711024,0.00020777807,0.00016808846,0.00062456523,0.00016329973,0.00039505266,0.000737837],"category_scores_gemma":[0.0037811943,0.00019471526,0.0003283491,0.00024401404,0.00023577585,0.00045836903,0.00021041388,0.0007889652,0.00019267744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17999955,0.0043648384,0.391307,0.0005138913,0.0016055498,0.0014083644,0.0011720246,0.011543687,0.12978005,0.00051831565,0.0022696222,0.2755171],"study_design_scores_gemma":[0.0071173236,0.20553517,0.73350704,0.00005882797,0.00076821615,0.0037899916,0.00028897187,0.027549094,0.016233483,0.000524313,0.0045383014,0.00008928306],"about_ca_topic_score_codex":0.00043317376,"about_ca_topic_score_gemma":0.00028628335,"teacher_disagreement_score":0.0013240675,"about_ca_system_score_codex":0.00039324068,"about_ca_system_score_gemma":0.00029626652,"threshold_uncertainty_score":0.007002473},"labels":[],"label_agreement":null},{"id":"W3008901859","doi":"10.1002/cpdd.773","title":"Absolute Bioavailability of Vemurafenib in Patients With <i>BRAF</i><sup>V600</sup> Mutation–Positive Malignancies","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Vemurafenib; Medicine; Bioavailability; Mutation; Internal medicine; Cancer research; Oncology; Pharmacology; Cancer; Genetics; Metastatic melanoma; Gene","score_opus":0.018109760222120016,"score_gpt":0.28101741849757805,"score_spread":0.26290765827545803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008901859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990934,0.00035503553,0.00024107545,0.000026261554,0.0000040203677,0.00002316339,0.00005693867,0.000015327467,0.00018478537],"genre_scores_gemma":[0.9994041,0.00007420687,0.00018184076,0.000041472143,0.000010016284,0.000018930576,0.00011806104,0.0000034349741,0.00014794155],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998367,0.000058274523,0.000010022761,0.000042795502,0.000026474641,0.000025692598],"domain_scores_gemma":[0.999686,0.00009615094,0.00010830509,0.000016431834,0.000025144647,0.00006794431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042125053,0.00028364122,0.00074201415,0.000146304,0.00021361098,0.0003299957,0.0001261436,0.00029347467,0.00079532736],"category_scores_gemma":[0.0007670475,0.00019966153,0.00028235262,0.000090977905,0.00015269159,0.00035323665,0.0001463876,0.0005784933,0.00018794108],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16023341,0.0050740056,0.36115885,0.00027847185,0.0006235663,0.0013166876,0.00050764956,0.004577148,0.35028547,0.0001996797,0.00186648,0.1138786],"study_design_scores_gemma":[0.010565607,0.17584161,0.73059964,0.00003345158,0.00079957594,0.0038119126,0.00025294285,0.01251976,0.060341988,0.000294458,0.0048567946,0.00008227774],"about_ca_topic_score_codex":0.00043667978,"about_ca_topic_score_gemma":0.00039099876,"teacher_disagreement_score":0.00079532736,"about_ca_system_score_codex":0.0003006304,"about_ca_system_score_gemma":0.00024522564,"threshold_uncertainty_score":0.0026606321},"labels":[],"label_agreement":null},{"id":"W3011153961","doi":"10.1002/cpdd.789","title":"The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Bioequivalence; Dosing; Tolerability; Pharmacology; Crossover study; Pharmacokinetics; Internal medicine; Placebo; Adverse effect","score_opus":0.03342460266546551,"score_gpt":0.3503987466890036,"score_spread":0.31697414402353813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011153961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976719,0.0005248436,0.0006811122,0.000030985106,0.0000745263,0.00043748232,0.00018150515,0.000025188936,0.0003723848],"genre_scores_gemma":[0.9966446,0.00032445684,0.0010600005,0.00013512507,0.000095215815,0.000564826,0.0003061537,0.000015615184,0.0008539972],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9975211,0.0012480653,0.0001771506,0.0005608899,0.000337512,0.000155243],"domain_scores_gemma":[0.99856806,0.0004638801,0.00032662752,0.00023973503,0.00016827186,0.00023335202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034959454,0.0009198753,0.0013533906,0.00043629739,0.00036044398,0.00062478404,0.00047064605,0.0015273723,0.0020225786],"category_scores_gemma":[0.0032236606,0.0008031015,0.0008131546,0.00031063837,0.0009870257,0.000986559,0.00036864867,0.0011027104,0.00079779583],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7641966,0.021351459,0.0062866304,0.00043321608,0.00070018315,0.0001700629,0.0008568504,0.0008198224,0.16786893,0.0003110323,0.00066780025,0.036337394],"study_design_scores_gemma":[0.0654442,0.82592416,0.06733806,0.000046147838,0.00094085274,0.0003586251,0.00024963278,0.00507088,0.031836525,0.00032812828,0.0023483026,0.00011454599],"about_ca_topic_score_codex":0.00067001267,"about_ca_topic_score_gemma":0.00049905793,"teacher_disagreement_score":0.0034959454,"about_ca_system_score_codex":0.00032279265,"about_ca_system_score_gemma":0.0005053749,"threshold_uncertainty_score":0.018488526},"labels":[],"label_agreement":null},{"id":"W3017244061","doi":"10.1002/cpdd.788","title":"Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With <i>BRAF</i><sup>V600</sup> Mutation–Positive Malignancies","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Pharmacokinetics; Vemurafenib; Pharmacology; Mutation; Oncology; Internal medicine; Cancer research; Genetics; Cancer; Gene","score_opus":0.018069228122625944,"score_gpt":0.2851740033891128,"score_spread":0.26710477526648685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017244061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992199,0.00039635593,0.00015857026,0.000033452754,0.000013226524,0.000032715427,0.00003858001,0.000011058575,0.00009612765],"genre_scores_gemma":[0.999374,0.00012238955,0.0002731246,0.000032961256,0.000021643005,0.00003615621,0.000054090924,0.0000036825138,0.00008190543],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993851,0.0003398529,0.000031394007,0.0001035889,0.00006832654,0.00007156389],"domain_scores_gemma":[0.9990163,0.00036126902,0.00030752996,0.00008014636,0.000038223752,0.00019657343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011889974,0.0006086488,0.0013063212,0.0001733637,0.0001833748,0.0005070816,0.0002956238,0.000441695,0.0006648109],"category_scores_gemma":[0.0017860245,0.00037449884,0.001105206,0.00018775373,0.0003973718,0.0005154914,0.00017555413,0.0014069002,0.00011285601],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.663625,0.018710861,0.036349908,0.00030011495,0.0026898952,0.0002747547,0.00025603056,0.009564163,0.11758916,0.00014407908,0.0008927703,0.14960326],"study_design_scores_gemma":[0.08254845,0.74300325,0.13401641,0.00002519327,0.001326345,0.00061206636,0.00009320005,0.0121337855,0.024295779,0.00019333113,0.0016805207,0.00007165153],"about_ca_topic_score_codex":0.00043212285,"about_ca_topic_score_gemma":0.0007350056,"teacher_disagreement_score":0.0013063212,"about_ca_system_score_codex":0.00056573114,"about_ca_system_score_gemma":0.0005318421,"threshold_uncertainty_score":0.0062880516},"labels":[],"label_agreement":null},{"id":"W3038254578","doi":"10.1002/cpdd.822","title":"Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady‐State Pharmacokinetics of Vemurafenib in Patients With <i>BRAF</i><sup>V600</sup> Mutation–Positive Malignancies","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Vemurafenib; Itraconazole; Medicine; Pharmacokinetics; Dosing; Pharmacology; Crossover study; Confidence interval; Area under the curve; Internal medicine; Adverse effect; Urology; Gastroenterology; Cancer; Dermatology; Pathology; Metastatic melanoma","score_opus":0.012223719638403855,"score_gpt":0.2778418450221536,"score_spread":0.26561812538374974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038254578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992187,0.00027014918,0.00010623234,0.00003366413,0.000009181433,0.00001738605,0.00004206845,0.000010944152,0.00029167836],"genre_scores_gemma":[0.999413,0.00009329964,0.00014671487,0.0000255985,0.000015357422,0.000018101715,0.00008158744,0.0000025923512,0.00020377776],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99966276,0.00014226291,0.000024049077,0.000058734517,0.000043884695,0.00006830043],"domain_scores_gemma":[0.9993755,0.00023370981,0.00014842105,0.000046976664,0.000032464744,0.00016286211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057325204,0.0002694067,0.0006497716,0.00013457186,0.00012818066,0.00032381905,0.00012705455,0.00023968276,0.0008935453],"category_scores_gemma":[0.0013236577,0.00020613316,0.0005806236,0.00020041685,0.0001976445,0.00035430578,0.00014878725,0.00079945975,0.00013107529],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30035317,0.017090535,0.09210833,0.0002558295,0.0020032404,0.00088616804,0.000458847,0.010560349,0.28821024,0.00022357513,0.001780956,0.28606883],"study_design_scores_gemma":[0.0120323375,0.3327371,0.5794472,0.000024527564,0.0013085362,0.0013178756,0.00012950419,0.013510448,0.056008704,0.00018480854,0.0032134976,0.0000854319],"about_ca_topic_score_codex":0.000555387,"about_ca_topic_score_gemma":0.0011982624,"teacher_disagreement_score":0.0008935453,"about_ca_system_score_codex":0.00036698818,"about_ca_system_score_gemma":0.0003931908,"threshold_uncertainty_score":0.003031671},"labels":[],"label_agreement":null},{"id":"W3091934681","doi":"10.1002/cpdd.871","title":"Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Trypanosoma species research and implications","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Bayer","keywords":"Bioequivalence; Cmax; Medicine; Dosing; Bioavailability; Pharmacology; Confidence interval; Pharmacokinetics; Internal medicine","score_opus":0.06803022149680939,"score_gpt":0.3917060144841638,"score_spread":0.32367579298735444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091934681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971276,0.001538121,0.00051826576,0.00006028868,0.000017261107,0.0001229746,0.00017200202,0.000008582877,0.00043494624],"genre_scores_gemma":[0.9983683,0.00029048143,0.0008752193,0.000070614726,0.000022290416,0.000069499,0.0001689516,0.0000030807937,0.00013162219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993581,0.0003088472,0.00007446199,0.00007053968,0.00015601215,0.00003194152],"domain_scores_gemma":[0.99876654,0.00054815394,0.00041983277,0.00004670582,0.00009998947,0.00011877011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009837332,0.00021452825,0.0005205282,0.00026896887,0.0001350856,0.00030946216,0.00014964308,0.00048364984,0.0009163914],"category_scores_gemma":[0.002786091,0.00012477157,0.0004353315,0.00022314984,0.00016066068,0.00023878792,0.00009515241,0.00041048136,0.00017113416],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18105459,0.011044291,0.13778096,0.0011923529,0.0013027188,0.0014908598,0.0007475389,0.0032300442,0.39823717,0.0004651312,0.0022003767,0.26125392],"study_design_scores_gemma":[0.012260851,0.26982424,0.6388071,0.00009012928,0.0009398518,0.0024763758,0.00027260743,0.008750259,0.061236333,0.00017221722,0.005074958,0.00009505297],"about_ca_topic_score_codex":0.00036893733,"about_ca_topic_score_gemma":0.00038308138,"teacher_disagreement_score":0.0009837332,"about_ca_system_score_codex":0.00020275214,"about_ca_system_score_gemma":0.00018840577,"threshold_uncertainty_score":0.005202532},"labels":[],"label_agreement":null},{"id":"W3095574760","doi":"10.1002/cpdd.884","title":"Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metformin; Bioequivalence; Medicine; Crossover study; Pharmacology; Type 2 diabetes; Pharmacokinetics; Confidence interval; Diabetes mellitus; Internal medicine; Endocrinology; Placebo","score_opus":0.05629632715691588,"score_gpt":0.35134043514486146,"score_spread":0.29504410798794556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095574760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985763,0.0005263529,0.00035915346,0.000017429687,0.000019901325,0.00013438707,0.00013742644,0.00000914253,0.00021991595],"genre_scores_gemma":[0.99743265,0.0003474411,0.0013931455,0.000045219887,0.0000149996395,0.00010650867,0.00024118641,0.0000060763978,0.00041280373],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9981499,0.0008497333,0.000097532335,0.00028972185,0.0004948138,0.000118427895],"domain_scores_gemma":[0.9994523,0.00011317005,0.00017946305,0.00006474548,0.000084961,0.00010541359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017790223,0.00038201868,0.0009614125,0.00038772848,0.00025474277,0.00056535384,0.00042835748,0.0005700888,0.0007383173],"category_scores_gemma":[0.0022740448,0.00040611526,0.00060501,0.0005500118,0.0005705498,0.00041783246,0.00019349763,0.00084373984,0.00011803214],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40307403,0.0082332445,0.008074129,0.00050659844,0.0012081591,0.00009543381,0.0005814243,0.0021352689,0.5017388,0.00037347214,0.0006102323,0.073369354],"study_design_scores_gemma":[0.046005506,0.5650644,0.16318627,0.00009572073,0.0022042058,0.00036818223,0.00027106225,0.011667975,0.2050854,0.00017418206,0.0056753405,0.00020174356],"about_ca_topic_score_codex":0.010180881,"about_ca_topic_score_gemma":0.012435316,"teacher_disagreement_score":0.010180881,"about_ca_system_score_codex":0.0013240795,"about_ca_system_score_gemma":0.0015240685,"threshold_uncertainty_score":0.020243287},"labels":[],"label_agreement":null},{"id":"W3113925818","doi":"10.1002/cpdd.894","title":"Comparison of Steroidogenic Exposure Following the Administration of Repository Corticotropin Injection With a Synthetic ACTH<sub>1‐24</sub> Depot and Methylprednisolone in Healthy Subjects","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Adrenal Hormones and Disorders","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Depot; Prednisone; Methylprednisolone; Internal medicine; Pharmacodynamics; Subcutaneous injection; Pharmacokinetics; Adrenocorticotropic hormone; Endocrinology; Pharmacology; Hormone","score_opus":0.05146719463994026,"score_gpt":0.3778594674939645,"score_spread":0.3263922728540242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113925818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988726,0.00041129658,0.00038553137,0.000010897781,0.0000056765803,0.00003213671,0.00008762532,0.00001304372,0.00018112271],"genre_scores_gemma":[0.99936754,0.000093713345,0.00021399258,0.00003222272,0.000010333089,0.00002579849,0.00013099381,0.000003614493,0.00012181435],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99942905,0.000234483,0.00002590486,0.000104270825,0.00015955495,0.000046780948],"domain_scores_gemma":[0.9992268,0.0003515829,0.000193789,0.000071544906,0.00004278057,0.00011351253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084660243,0.00037870844,0.0004967876,0.00019986076,0.00012860744,0.0003867213,0.0001526354,0.00043568434,0.0006296572],"category_scores_gemma":[0.0013342476,0.00025271843,0.0003525107,0.00015143014,0.00028881122,0.00022529988,0.00012594288,0.00042132242,0.00018310102],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13146038,0.006462461,0.3192565,0.0004177336,0.0015450668,0.0014984395,0.00078800967,0.006713286,0.447373,0.00024469997,0.0007141313,0.08352627],"study_design_scores_gemma":[0.0026637798,0.22112426,0.7012432,0.000023458928,0.0007389617,0.002071677,0.00026800967,0.008563947,0.061140608,0.00020249038,0.001906589,0.000052901923],"about_ca_topic_score_codex":0.0009027248,"about_ca_topic_score_gemma":0.00063068664,"teacher_disagreement_score":0.0009027248,"about_ca_system_score_codex":0.00024772107,"about_ca_system_score_gemma":0.00027665807,"threshold_uncertainty_score":0.0044773817},"labels":[],"label_agreement":null},{"id":"W3119947423","doi":"10.1002/cpdd.901","title":"A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Warfarin; Bioequivalence; Pharmacokinetics; Clonazepam; Crossover study; Pharmacology; Cmax; Concomitant; Pharmacodynamics; Drug; Internal medicine; Placebo","score_opus":0.16681087861956184,"score_gpt":0.497394297777827,"score_spread":0.33058341915826517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119947423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99894017,0.00036353854,0.00018494885,0.000028744129,0.000028378165,0.00008591566,0.000115718816,0.000015109696,0.00023749395],"genre_scores_gemma":[0.9990308,0.00011051029,0.00022486916,0.00007889879,0.000033666533,0.00005837951,0.00011092726,0.00000457982,0.00034732278],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992163,0.00037192996,0.000048387916,0.00016941971,0.00011468301,0.000079211575],"domain_scores_gemma":[0.9994479,0.00015230777,0.0001540855,0.00007507165,0.00004551858,0.00012511302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010196111,0.00054628454,0.0010097321,0.00016791737,0.0003248122,0.0003446072,0.00019538254,0.0008938445,0.0018087107],"category_scores_gemma":[0.0014476996,0.00032240208,0.00051370426,0.00017032704,0.0005920607,0.0003734343,0.00017217545,0.0005457719,0.00031794075],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74923384,0.01375313,0.02887851,0.0004074766,0.0011347143,0.0002844903,0.00033733173,0.00041398362,0.16571273,0.0001239547,0.0009706301,0.038749177],"study_design_scores_gemma":[0.048238363,0.7223735,0.19966057,0.00003129224,0.0012594564,0.0005948122,0.00018100328,0.001628385,0.022459902,0.00014604176,0.003367141,0.000059649792],"about_ca_topic_score_codex":0.0011699949,"about_ca_topic_score_gemma":0.0011900942,"teacher_disagreement_score":0.0018087107,"about_ca_system_score_codex":0.00025030534,"about_ca_system_score_gemma":0.0003421639,"threshold_uncertainty_score":0.006050706},"labels":[],"label_agreement":null},{"id":"W3120034421","doi":"10.1002/cpdd.904","title":"Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"PTC Therapeutics","keywords":"Medicine; Pharmacokinetics; Tubulin; Pharmacology; Microtubule","score_opus":0.027670907593689963,"score_gpt":0.3555511339723538,"score_spread":0.3278802263786638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120034421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780625,0.0009419177,0.00042561753,0.00004100173,0.000009216152,0.000111206675,0.00016469437,0.000037976177,0.0004621171],"genre_scores_gemma":[0.9978123,0.00056634285,0.0004119963,0.00006889741,0.000031521486,0.00007282606,0.00031961396,0.000012408707,0.00070407835],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998572,0.0000534322,0.0000068449585,0.000027760841,0.00003435711,0.000020440126],"domain_scores_gemma":[0.99975115,0.000057448655,0.000074416086,0.000014976091,0.000031649284,0.00007033267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003785834,0.0003003528,0.00065744185,0.00016796812,0.00025446384,0.0002831109,0.00014427459,0.00036068854,0.0007304884],"category_scores_gemma":[0.00052477786,0.00019620621,0.00024086988,0.00023212112,0.00028664686,0.0002808893,0.000085034146,0.0008029114,0.00029214832],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13707405,0.0121492585,0.028736267,0.00047049276,0.00043243452,0.00088126794,0.0007089299,0.0035637987,0.64650893,0.00023595661,0.002492623,0.16674596],"study_design_scores_gemma":[0.020448228,0.6270453,0.25028917,0.000043509306,0.000755056,0.0023763345,0.00025476323,0.008954805,0.07969835,0.00035152098,0.0097003095,0.00008262201],"about_ca_topic_score_codex":0.0010506446,"about_ca_topic_score_gemma":0.0011647413,"teacher_disagreement_score":0.0010506446,"about_ca_system_score_codex":0.00037371172,"about_ca_system_score_gemma":0.0004071188,"threshold_uncertainty_score":0.0027114153},"labels":[],"label_agreement":null},{"id":"W3133802300","doi":"10.1002/cpdd.926","title":"Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Telmisartan; Rosuvastatin; Ezetimibe; Pharmacokinetic interaction; Pharmacology; Pharmacokinetics; Internal medicine; Drug interaction; Statin; Blood pressure","score_opus":0.03683423971864972,"score_gpt":0.3937161031873667,"score_spread":0.356881863468717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133802300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636614,0.001973376,0.00101499,0.00006806695,0.000033449658,0.000120101715,0.00011118923,0.000029815674,0.00028265346],"genre_scores_gemma":[0.9987311,0.0002552188,0.0006243542,0.00005774525,0.000046075504,0.00004435613,0.00006742823,0.000004684711,0.00016902426],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980521,0.0012039527,0.00009172214,0.00020895152,0.00034794494,0.00009534082],"domain_scores_gemma":[0.99856585,0.00063008786,0.00040794292,0.00010702589,0.00007430625,0.0002148204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023216433,0.0005280345,0.0016093005,0.00026953517,0.00017718843,0.0005620841,0.00030684864,0.0005626839,0.001227791],"category_scores_gemma":[0.0023424537,0.0003665658,0.00085952244,0.000226227,0.00045060716,0.00055906444,0.00017615309,0.0010074616,0.0001711601],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7374833,0.0071944306,0.060329366,0.0005299331,0.005369873,0.00040649093,0.00018013858,0.0024028756,0.117386594,0.0002674269,0.00043873818,0.06801092],"study_design_scores_gemma":[0.10323393,0.4322303,0.38749683,0.00004560396,0.0066444688,0.0011918205,0.000209255,0.020605762,0.044738423,0.0007936745,0.002695084,0.00011482231],"about_ca_topic_score_codex":0.0004021255,"about_ca_topic_score_gemma":0.0004938547,"teacher_disagreement_score":0.0023216433,"about_ca_system_score_codex":0.0004060738,"about_ca_system_score_gemma":0.00038746008,"threshold_uncertainty_score":0.012278199},"labels":[],"label_agreement":null},{"id":"W3172814721","doi":"10.1002/cpdd.953","title":"Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacokinetics; Medicine; Drug; Tolerability; Pharmacology; Adverse effect; Drug interaction; Internal medicine","score_opus":0.16431230472200548,"score_gpt":0.4857998073438024,"score_spread":0.32148750262179693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172814721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986664,0.00057464914,0.00020371933,0.000042996155,0.000009759485,0.00011941395,0.00016169068,0.000014822601,0.00020650144],"genre_scores_gemma":[0.99735236,0.0006328294,0.00063520804,0.00016977947,0.000037370224,0.00011760358,0.000344857,0.000013637459,0.0006964198],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999506,0.00022163715,0.000031608135,0.00010728778,0.00008170668,0.00005170401],"domain_scores_gemma":[0.9993154,0.00017428365,0.00022422023,0.00004377976,0.000051371408,0.00019098393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097129337,0.0006714842,0.00094004686,0.00027122366,0.0003586903,0.00030710502,0.00023406239,0.00045734862,0.0024653957],"category_scores_gemma":[0.0010450159,0.00034266108,0.00071612967,0.00019906713,0.00037617446,0.00035056772,0.0001931872,0.0006449248,0.00036850126],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30726677,0.054510463,0.079014145,0.00089491834,0.003929268,0.0013069205,0.0010888688,0.0018087787,0.41928607,0.00012994667,0.0020407054,0.12872314],"study_design_scores_gemma":[0.032289907,0.59952915,0.32719666,0.000033979577,0.0021309666,0.0021145719,0.00021635595,0.0022476723,0.028882692,0.00009000975,0.005183019,0.000085128864],"about_ca_topic_score_codex":0.00078914897,"about_ca_topic_score_gemma":0.0018240398,"teacher_disagreement_score":0.0024653957,"about_ca_system_score_codex":0.0003404803,"about_ca_system_score_gemma":0.00044420123,"threshold_uncertainty_score":0.008247554},"labels":[],"label_agreement":null},{"id":"W3200515041","doi":"10.1002/cpdd.1020","title":"Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH<sub>1‐24</sub> Depot and Methylprednisolone in Healthy Subjects","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Adrenal Hormones and Disorders","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Depot; Medicine; Pharmacodynamics; Adrenocorticotropic hormone; Pharmacokinetics; Methylprednisolone; Internal medicine; Endocrinology; Corticosteroid; Pharmacology; Hormone","score_opus":0.025231091828969862,"score_gpt":0.34140215033178634,"score_spread":0.31617105850281646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200515041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989371,0.00048892596,0.00018706592,0.000022066499,0.000019257463,0.00007644141,0.00009248961,0.000017534856,0.0001591141],"genre_scores_gemma":[0.998804,0.0001537444,0.00034802483,0.000083245795,0.000046260455,0.00010292775,0.00016027786,0.000006667877,0.00029482535],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99942833,0.00026763178,0.000027695187,0.00013023643,0.0000855791,0.000060589828],"domain_scores_gemma":[0.9991854,0.00031298728,0.00016862465,0.00005735474,0.000040815845,0.00023472715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090230646,0.0005623341,0.00085634604,0.00021899183,0.00021779141,0.00044597045,0.00022351458,0.0006997232,0.0010644596],"category_scores_gemma":[0.001484526,0.00045905556,0.00045547888,0.00015812306,0.0005167873,0.00043961074,0.00013793148,0.00073047477,0.00031959335],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7282082,0.015197636,0.037907254,0.0002629405,0.00079303863,0.00043191854,0.00034512495,0.0016116776,0.15743767,0.00012467959,0.0007057573,0.05697421],"study_design_scores_gemma":[0.052730408,0.752795,0.16871895,0.000019504729,0.00059851335,0.0006685389,0.0001178944,0.00460076,0.01824462,0.00014366636,0.001284817,0.00007736527],"about_ca_topic_score_codex":0.00049729715,"about_ca_topic_score_gemma":0.00043966097,"teacher_disagreement_score":0.0010644596,"about_ca_system_score_codex":0.0002769563,"about_ca_system_score_gemma":0.0003567327,"threshold_uncertainty_score":0.004771948},"labels":[],"label_agreement":null},{"id":"W3215986232","doi":"10.1002/cpdd.1043","title":"The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P‐Glycoprotein Substrate Digoxin in Healthy Volunteers","year":2021,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Digoxin; Medicine; Pharmacokinetics; Pharmacology; Tolerability; Oral administration; Crossover study; Internal medicine; Placebo; Adverse effect; Heart failure","score_opus":0.07222058166040611,"score_gpt":0.4252310117062345,"score_spread":0.3530104300458284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215986232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847347,0.00047274574,0.00023875182,0.00002848646,0.00003916108,0.00018059283,0.00010160092,0.000024793642,0.0004404166],"genre_scores_gemma":[0.99786854,0.00033174682,0.00045634314,0.00009647986,0.00008144394,0.00018327615,0.00019415819,0.000015557805,0.0007725404],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992613,0.00032004545,0.00003513341,0.00020704618,0.00007562005,0.00010076921],"domain_scores_gemma":[0.99923813,0.0002542813,0.000108249034,0.00007871583,0.000072851915,0.0002476919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010477658,0.0008493169,0.0013461976,0.00019891912,0.00038746282,0.00057851593,0.00025635815,0.00090939994,0.0013743764],"category_scores_gemma":[0.0018871884,0.00053685304,0.00042273308,0.00015961897,0.000589561,0.0004520204,0.000286172,0.0010116324,0.00045112308],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6252139,0.025755975,0.014655704,0.0003469055,0.0004309259,0.0006989056,0.00066482456,0.0007554918,0.25971997,0.00009830292,0.0008868635,0.07077212],"study_design_scores_gemma":[0.016650105,0.84858346,0.09226369,0.000023343853,0.0005368083,0.0006736588,0.00018338788,0.002301798,0.036801316,0.00015383247,0.0017556087,0.00007306147],"about_ca_topic_score_codex":0.0008322797,"about_ca_topic_score_gemma":0.0008475169,"teacher_disagreement_score":0.0013743764,"about_ca_system_score_codex":0.00026761572,"about_ca_system_score_gemma":0.000497295,"threshold_uncertainty_score":0.005541146},"labels":[],"label_agreement":null},{"id":"W4220822477","doi":"10.1002/cpdd.1089","title":"Effect of Colonic Absorption on the Pharmacokinetic Properties of Delayed‐Release and Extended‐Release Methylphenidate: In Vivo, In Vitro, and Modeling Evaluations","year":2022,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viron Therapeutics (Canada)","funders":"","keywords":"Pharmacokinetics; Methylphenidate; Bioavailability; Pharmacology; Absorption (acoustics); Morning; Medicine; Crossover study; In vivo; Gastrointestinal tract; Small intestine; Evening; Internal medicine; Attention deficit hyperactivity disorder; Biology; Materials science; Placebo; Psychiatry; Pathology","score_opus":0.0722415416888,"score_gpt":0.4134766494053294,"score_spread":0.34123510771652943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220822477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926407,0.0025927825,0.0028834806,0.00009697505,0.000057567704,0.00008939819,0.00052878074,0.000050083327,0.0010603731],"genre_scores_gemma":[0.9892358,0.004174274,0.0047805435,0.00008273859,0.000025959283,0.00008073213,0.00051389757,0.000044423152,0.0010616669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996929,0.00007787419,0.000017477842,0.00006672778,0.00009036114,0.0000546692],"domain_scores_gemma":[0.9994704,0.00021596566,0.00011754152,0.000042872372,0.00010747331,0.000045657252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052796863,0.00048686643,0.00056756585,0.00014743627,0.00019812185,0.0005724372,0.00031140365,0.00038757402,0.0012707653],"category_scores_gemma":[0.00088741677,0.00036400228,0.0006432738,0.00023898586,0.00022111658,0.00054915977,0.0002425483,0.00085200067,0.00025795033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012810689,0.00081004074,0.002902117,0.00069825846,0.00020746476,0.00032951156,0.00020250722,0.007839599,0.952849,0.00019581024,0.00042440995,0.020730557],"study_design_scores_gemma":[0.0007406893,0.022655798,0.01943877,0.00006381333,0.00069454755,0.0005724624,0.00024340859,0.058741197,0.8900916,0.00012964668,0.0065185446,0.00010942288],"about_ca_topic_score_codex":0.0052143,"about_ca_topic_score_gemma":0.0045989226,"teacher_disagreement_score":0.0052143,"about_ca_system_score_codex":0.0004967826,"about_ca_system_score_gemma":0.0005842179,"threshold_uncertainty_score":0.01036793},"labels":[],"label_agreement":null},{"id":"W4293367557","doi":"10.1002/cpdd.1153","title":"Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors","year":2022,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Bioavailability; Pharmacokinetics; Medicine; Pharmacology; Tolerability; Bioequivalence; Chemistry; Adverse effect","score_opus":0.23958492077186636,"score_gpt":0.4805594073694024,"score_spread":0.24097448659753604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293367557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921938,0.0016721009,0.003828291,0.0000744069,0.00009907545,0.00082291325,0.00039398237,0.000054674598,0.00086063094],"genre_scores_gemma":[0.9948318,0.0005401553,0.003018276,0.00007673333,0.00006921591,0.00052336074,0.00030874292,0.000017688399,0.00061393547],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9976036,0.0012645898,0.00015935228,0.00035518935,0.00051394326,0.00010331967],"domain_scores_gemma":[0.99903274,0.0002514012,0.00029899075,0.000114051756,0.00018588782,0.00011689233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028211316,0.00041008962,0.0011794228,0.0003597982,0.0003039278,0.0007774556,0.00045020206,0.00079704094,0.001885996],"category_scores_gemma":[0.002627357,0.0002871786,0.0009953271,0.0005347438,0.0005146195,0.0006194096,0.0002625771,0.0011501433,0.0002959266],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20389812,0.017704023,0.0065556536,0.0012895374,0.0019260888,0.00020945177,0.00066378777,0.0026368627,0.6686315,0.001021683,0.0013550597,0.09410823],"study_design_scores_gemma":[0.028443385,0.7023322,0.05405485,0.00010758872,0.0033487333,0.0008522392,0.00025984342,0.015228233,0.18120787,0.00040614943,0.013608993,0.00014995047],"about_ca_topic_score_codex":0.0010453331,"about_ca_topic_score_gemma":0.0007617275,"teacher_disagreement_score":0.0028211316,"about_ca_system_score_codex":0.00040894092,"about_ca_system_score_gemma":0.0006268313,"threshold_uncertainty_score":0.014919758},"labels":[],"label_agreement":null},{"id":"W4318332812","doi":"10.1002/cpdd.1210","title":"A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers","year":2023,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Salix Pharmaceuticals; Bausch Health; Mitsubishi Tanabe Pharma Corporation","keywords":"Medicine; Placebo; Moxifloxacin; Crossover study; Dosing; QT interval; Anesthesia; Pharmacokinetics; Adverse effect; Confidence interval; Oral administration; Internal medicine; Antibiotics","score_opus":0.039471458823368014,"score_gpt":0.36662950945268197,"score_spread":0.32715805062931397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318332812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726926,0.00083898683,0.0032355066,0.00024164445,0.0007286488,0.02054978,0.000642486,0.00014628966,0.00092406874],"genre_scores_gemma":[0.93479496,0.00089859124,0.017468672,0.0012524902,0.0010201609,0.03942978,0.00082211394,0.00005472458,0.0042584096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996838,0.0014747679,0.00025548926,0.00069649285,0.00039446045,0.00034080603],"domain_scores_gemma":[0.996824,0.0008163371,0.0006131928,0.00057185674,0.00036504192,0.00080961984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056081773,0.0018345935,0.0055083884,0.00070333004,0.0011513634,0.0009849966,0.0014856629,0.0025597955,0.0037818248],"category_scores_gemma":[0.0039909817,0.001797082,0.0020959955,0.000523149,0.0024455031,0.0010799279,0.0007053454,0.0024977587,0.0008606165],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9478711,0.03385285,0.0005414805,0.00028630346,0.0004985237,0.000030239138,0.00009182235,0.000257434,0.010322133,0.00014990811,0.00029248762,0.005805735],"study_design_scores_gemma":[0.7171743,0.27921468,0.0015051932,0.0000097913635,0.00026846805,0.000021669872,0.000014530244,0.00031943014,0.00087664445,0.00011955142,0.00045451985,0.000021209698],"about_ca_topic_score_codex":0.00090745237,"about_ca_topic_score_gemma":0.0015285115,"teacher_disagreement_score":0.0056081773,"about_ca_system_score_codex":0.0007447774,"about_ca_system_score_gemma":0.0023784789,"threshold_uncertainty_score":0.029659212},"labels":[],"label_agreement":null},{"id":"W4384126864","doi":"10.1002/cpdd.1300","title":"Comparative Bioavailability of Two Daily Subcutaneous Doses Versus a Single Dose of Intramuscular and Vaginal Progesterone Formulations in Healthy Postmenopausal Females","year":2023,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Ovarian function and disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Bioavailability; Luteal phase; Crossover study; Pharmacokinetics; Estrous cycle; Internal medicine; Hormone; Pharmacology","score_opus":0.13826118681176483,"score_gpt":0.44333469550781796,"score_spread":0.3050735086960531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384126864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99946207,0.000227574,0.00010976355,0.00001476763,0.000010795084,0.00004674753,0.00003572903,0.000006287937,0.00008626917],"genre_scores_gemma":[0.99890137,0.00016086055,0.00039310855,0.000038646423,0.000043242628,0.00009225296,0.00006322465,0.0000038185703,0.00030354835],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995085,0.00022935729,0.000027683438,0.000094545576,0.00009119932,0.000048774713],"domain_scores_gemma":[0.99921405,0.0003288012,0.00018968982,0.0000676789,0.00006312712,0.00013667562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011884742,0.00040780727,0.0010045135,0.0003145531,0.0002519104,0.0002702227,0.0001982719,0.00051041285,0.0012818176],"category_scores_gemma":[0.0016665729,0.00033214386,0.00047461124,0.00016781413,0.00042472445,0.00033111792,0.0001583074,0.00064247946,0.00023200252],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70585304,0.019545503,0.020065328,0.0003658379,0.00043807994,0.00024560504,0.00047766298,0.00077186787,0.19957188,0.000092533686,0.00034790643,0.05222479],"study_design_scores_gemma":[0.02575746,0.8669224,0.082271785,0.000014543317,0.00040558426,0.00023580743,0.00016404386,0.0019010239,0.021507168,0.00006941286,0.0007198153,0.0000309011],"about_ca_topic_score_codex":0.00057019206,"about_ca_topic_score_gemma":0.00043082004,"teacher_disagreement_score":0.0012818176,"about_ca_system_score_codex":0.00021152888,"about_ca_system_score_gemma":0.00027077668,"threshold_uncertainty_score":0.00628531},"labels":[],"label_agreement":null},{"id":"W4390599050","doi":"10.1002/cpdd.1364","title":"Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CYP3A; CYP3A4; Tacrolimus; Pharmacology; Medicine; Pharmacokinetics; Drug interaction; CYP3A5; Calcineurin; Crossover study; P-glycoprotein; Pharmacokinetic interaction; Cmax; Inducer; Cytochrome P450; Internal medicine; Metabolism; Chemistry; Transplantation; Antibiotics; Biochemistry","score_opus":0.07446660461163242,"score_gpt":0.4725914293935504,"score_spread":0.398124824781918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390599050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998185,0.0011822442,0.00014159075,0.00002343,0.000041252944,0.00005385481,0.00006929063,0.000015891086,0.0002874979],"genre_scores_gemma":[0.9988105,0.0004019854,0.00023237636,0.000038235128,0.000056585726,0.0000458205,0.000089514855,0.0000072395887,0.00031784107],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99926406,0.00033129362,0.0000731702,0.00013328061,0.00012172359,0.00007641912],"domain_scores_gemma":[0.998955,0.0004644291,0.0002731781,0.000078932244,0.00006569481,0.0001627189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076361315,0.00038847048,0.00096275995,0.00016925785,0.00012484964,0.00040974104,0.0002211322,0.0005298137,0.0017239855],"category_scores_gemma":[0.0019511061,0.00019758513,0.0005752035,0.00021654322,0.00028243283,0.00036196117,0.00012599802,0.0005936159,0.00030392926],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5711684,0.008583002,0.004641489,0.0006172893,0.0008962883,0.00018962023,0.0001306981,0.0008130812,0.32946268,0.00009533649,0.00042613113,0.08297601],"study_design_scores_gemma":[0.026121475,0.7310467,0.090825364,0.00005582637,0.0016968973,0.00069694745,0.000081547594,0.0038453434,0.14328238,0.0000753328,0.002188061,0.000084142695],"about_ca_topic_score_codex":0.00022263487,"about_ca_topic_score_gemma":0.00023107864,"teacher_disagreement_score":0.0017239855,"about_ca_system_score_codex":0.00016029098,"about_ca_system_score_gemma":0.00015991941,"threshold_uncertainty_score":0.005767286},"labels":[],"label_agreement":null},{"id":"W4391362198","doi":"10.1002/cpdd.1381","title":"Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?","year":2024,"lang":"en","type":"letter","venue":"Clinical Pharmacology in Drug Development","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Nalmefene; Nasal administration; Opioid; Opioid overdose; Naltrexone; Anesthesia; Intensive care medicine; Narcotic antagonists; Pharmacology; (+)-Naloxone; Internal medicine","score_opus":0.04034816234880309,"score_gpt":0.40442199946430896,"score_spread":0.3640738371155059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391362198","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017203927,0.6196274,0.0019394327,0.29930955,0.036297906,0.00015190653,0.00097193423,0.00033642192,0.024161495],"genre_scores_gemma":[0.16401124,0.645553,0.0050627957,0.10856255,0.04321686,0.00023688734,0.0009416632,0.0001599686,0.032255042],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99949896,0.00015953007,0.00004402526,0.000048978967,0.00020337921,0.00004517911],"domain_scores_gemma":[0.9971967,0.0008326809,0.00056540925,0.00008289273,0.0010191475,0.00030326017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015347126,0.00032932722,0.00088384637,0.0005079681,0.0002451055,0.0010762371,0.00063042034,0.0018421401,0.018489875],"category_scores_gemma":[0.009258184,0.00009877657,0.00074677303,0.00021837444,0.00034457716,0.0013397422,0.00038812807,0.0016512555,0.0039010528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025689895,0.0006070588,0.0026172872,0.0032645408,0.0004099441,0.00019333343,0.00008919145,0.00012180195,0.000981072,0.0021453218,0.17016119,0.81684035],"study_design_scores_gemma":[0.0025919587,0.0049687447,0.023237253,0.010005731,0.0014068364,0.0011639656,0.0006407152,0.00083666126,0.0034462092,0.0063890303,0.9452066,0.000106362444],"about_ca_topic_score_codex":0.0023530717,"about_ca_topic_score_gemma":0.0057502845,"teacher_disagreement_score":0.018489875,"about_ca_system_score_codex":0.0005850468,"about_ca_system_score_gemma":0.001179083,"threshold_uncertainty_score":0.06185478},"labels":[],"label_agreement":null},{"id":"W4391607838","doi":"10.1002/cpdd.1383","title":"Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast‐Acting, Nondihydropyridine Calcium Channel Blocker","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada); Vertex Pharmaceuticals (Canada); Cégep de Saint-Laurent","funders":"","keywords":"Medicine; Pharmacodynamics; Calcium channel blocker; Pharmacokinetics; Nasal administration; Pharmacology; Calcium channel; Anesthesia; Calcium; Internal medicine","score_opus":0.038452549964604524,"score_gpt":0.3985359675126638,"score_spread":0.3600834175480593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391607838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975654,0.0007625234,0.0010765446,0.000030295005,0.000007729828,0.00009225767,0.00016060834,0.000020692998,0.0002839588],"genre_scores_gemma":[0.9965061,0.00051792397,0.0019610943,0.000079912665,0.000037629386,0.00016300193,0.00028092077,0.000010196116,0.00044319933],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99975866,0.00011404562,0.000019338737,0.000041460717,0.000047966372,0.0000185826],"domain_scores_gemma":[0.9996593,0.00012196419,0.00010633991,0.00003996854,0.000030207002,0.000042362553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052260724,0.00024324121,0.00045903344,0.0001009617,0.00010688879,0.00020878174,0.00012701262,0.00025567907,0.00059778156],"category_scores_gemma":[0.00089842244,0.00020273763,0.00025806052,0.00010771974,0.00021001641,0.00036889443,0.000078112374,0.000494864,0.00015758946],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054819327,0.002856647,0.021571618,0.00034253503,0.00042998279,0.00038261153,0.00043920754,0.0015527395,0.80811423,0.00012838966,0.0006042033,0.108758494],"study_design_scores_gemma":[0.014466868,0.41151354,0.36370373,0.00003052572,0.00096509064,0.0025772199,0.00021420611,0.0080724405,0.19284923,0.00023432009,0.0052914387,0.00008132619],"about_ca_topic_score_codex":0.00034187306,"about_ca_topic_score_gemma":0.00046872196,"teacher_disagreement_score":0.00059778156,"about_ca_system_score_codex":0.0001395871,"about_ca_system_score_gemma":0.00018963532,"threshold_uncertainty_score":0.0027638674},"labels":[],"label_agreement":null},{"id":"W4391745346","doi":"10.1002/cpdd.1379","title":"Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Pfizer","keywords":"Pharmacokinetics; Medicine; Pharmacodynamics; Dosing; Adverse effect; Pharmacology; Discontinuation; Internal medicine; Gastroenterology","score_opus":0.05411766612786526,"score_gpt":0.4104809408775827,"score_spread":0.3563632747497174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391745346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957165,0.00234548,0.00079898594,0.000049595998,0.000016973367,0.00016055195,0.00031691004,0.000026342748,0.0005686543],"genre_scores_gemma":[0.99590164,0.0014112028,0.001135796,0.00019014845,0.000064581945,0.00015582582,0.00048641313,0.000008198983,0.0006461731],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99950135,0.00019414179,0.000062407875,0.00010599175,0.00010456567,0.000031469448],"domain_scores_gemma":[0.99929404,0.00018998599,0.0002448738,0.00007731023,0.00007829631,0.000115439994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012072134,0.00051623146,0.0008241016,0.00019937029,0.00024060455,0.0003466283,0.00019925245,0.00050191,0.0012647056],"category_scores_gemma":[0.000981301,0.00024847043,0.0005159449,0.00018219923,0.00038138224,0.00040579325,0.00021733937,0.00075580995,0.0003572178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25556418,0.019275175,0.08309311,0.0013579119,0.002721895,0.0010264093,0.0010537675,0.0017253502,0.4191636,0.0001978868,0.0016444122,0.21317625],"study_design_scores_gemma":[0.0183625,0.6753013,0.24376127,0.00006237622,0.0018237288,0.0025768036,0.00024378984,0.0015571556,0.048903987,0.00020111186,0.007135259,0.00007067356],"about_ca_topic_score_codex":0.00022069829,"about_ca_topic_score_gemma":0.00035820057,"teacher_disagreement_score":0.0012647056,"about_ca_system_score_codex":0.00015770973,"about_ca_system_score_gemma":0.00022847812,"threshold_uncertainty_score":0.0063844323},"labels":[],"label_agreement":null},{"id":"W4392648981","doi":"10.1002/cpdd.1395","title":"Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Réseau Québécois de Recherche sur les Médicaments","keywords":"NONMEM; Tobramycin; Medicine; Population; Pharmacokinetics; Antibacterial agent; Dosing; Gentamicin; Statistics; Antibiotics; Pharmacology; Mathematics; Microbiology; Biology","score_opus":0.1347633873784191,"score_gpt":0.4706056355172811,"score_spread":0.335842248138862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392648981","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1587712,0.0010502363,0.8319443,0.00039589955,0.00009596763,0.0009334599,0.0008005739,0.0033930014,0.0026154504],"genre_scores_gemma":[0.47875947,0.00033350327,0.5152852,0.00031473133,0.0000639647,0.0015181331,0.0015385544,0.0013123133,0.00087410654],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9515658,0.041741263,0.0017827442,0.0017133704,0.0028746428,0.00032217157],"domain_scores_gemma":[0.7809243,0.19145034,0.010354182,0.005707101,0.010739419,0.0008245509],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08186495,0.0027241157,0.0022175817,0.0019883458,0.0008029657,0.00223884,0.0019462912,0.0019018911,0.002334797],"category_scores_gemma":[0.13662332,0.0011627261,0.00243545,0.00082890724,0.0010450344,0.002026386,0.0032998794,0.0020044146,0.0004867059],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006706469,0.0007220827,0.028298369,0.0023678888,0.0038844913,0.0004354616,0.0011357322,0.78731847,0.0064869546,0.0077784234,0.0029720182,0.1518937],"study_design_scores_gemma":[0.00018445004,0.00080187793,0.002979287,0.0001468557,0.0001911799,0.00010576722,0.000121836856,0.98836786,0.0037450204,0.0019856184,0.0013060285,0.00006431774],"about_ca_topic_score_codex":0.0029087632,"about_ca_topic_score_gemma":0.002970719,"teacher_disagreement_score":0.91813505,"about_ca_system_score_codex":0.00092635973,"about_ca_system_score_gemma":0.0025270828,"threshold_uncertainty_score":0.4329484},"labels":[],"label_agreement":null},{"id":"W4400593447","doi":"10.1002/cpdd.1436","title":"Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"","keywords":"Medicine; Pharmacokinetics; Crossover study; Placebo; Internal medicine; Tolerability; Area under the curve; Oral administration; Gastroenterology; Randomized controlled trial; Pharmacology; Adverse effect; Pathology","score_opus":0.03734745860357723,"score_gpt":0.4049165509674602,"score_spread":0.36756909236388297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400593447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99917185,0.00024647728,0.00008799228,0.000018829356,0.000010500684,0.00006108956,0.00010512312,0.000004559221,0.00029354912],"genre_scores_gemma":[0.9988109,0.00009349131,0.0002328214,0.0001237508,0.000015646647,0.00011315234,0.00017102595,0.0000041615604,0.00043508402],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995435,0.00014708232,0.0000368554,0.00014710253,0.000055959947,0.00006941796],"domain_scores_gemma":[0.9994493,0.000080159094,0.00012743687,0.00006529728,0.00009496976,0.00018282852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010949716,0.00046337038,0.0007105542,0.00021522176,0.00065445894,0.0003122069,0.00018506015,0.0005706297,0.0018257091],"category_scores_gemma":[0.0013102943,0.0003291555,0.00053579203,0.0002228989,0.0003500536,0.00034013833,0.0002552543,0.00047119075,0.0003277958],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34869674,0.011511514,0.44472936,0.0008548824,0.0022926,0.0013597577,0.005294506,0.00038988155,0.13154684,0.0002542307,0.0021096817,0.050960183],"study_design_scores_gemma":[0.009016111,0.06573405,0.9138623,0.000023951796,0.0015791003,0.00075907016,0.000897,0.0006994943,0.0036359646,0.00011611945,0.0036007687,0.00007604362],"about_ca_topic_score_codex":0.002859116,"about_ca_topic_score_gemma":0.0033472136,"teacher_disagreement_score":0.002859116,"about_ca_system_score_codex":0.00024372057,"about_ca_system_score_gemma":0.00033397024,"threshold_uncertainty_score":0.0061076283},"labels":[],"label_agreement":null},{"id":"W4406772778","doi":"10.1002/cpdd.1509","title":"Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Kruppel-like factors research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Gilead Sciences","keywords":"Medicine; Moxifloxacin; QT interval; Placebo; Adverse effect; Dosing; Crossover study; Confidence interval; Pharmacology; Discontinuation; Pharmacokinetics; Anesthesia; Internal medicine; Antibiotics","score_opus":0.03976649950671286,"score_gpt":0.4610328291571056,"score_spread":0.42126632965039273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406772778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861805,0.0069333897,0.001872243,0.00018639675,0.00013807963,0.002946418,0.00069697195,0.000095305884,0.00095073134],"genre_scores_gemma":[0.98991966,0.0029069681,0.0022754907,0.00040205612,0.00036024099,0.0027150218,0.00054720236,0.000026848496,0.0008464174],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99810994,0.0010531845,0.0001665873,0.0003259438,0.00020804218,0.00013639004],"domain_scores_gemma":[0.9980117,0.0005527205,0.00068196637,0.0002587011,0.00015809044,0.00033679578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034026385,0.0015377275,0.004277861,0.00037097975,0.0003958121,0.0005313058,0.0008023339,0.0016326195,0.0031054826],"category_scores_gemma":[0.0028907463,0.0006056839,0.0018585455,0.00042400722,0.0008132124,0.0008167727,0.00040319088,0.0013215578,0.00037171628],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8890333,0.0096214535,0.0026662692,0.0018944727,0.0035228769,0.0001246954,0.00014668712,0.0004761234,0.04880113,0.00017949085,0.0004970956,0.043036453],"study_design_scores_gemma":[0.51421094,0.45397374,0.021647986,0.00006479457,0.0026258612,0.00017551519,0.000029577966,0.000535728,0.004787271,0.00016018818,0.0017495144,0.000039010163],"about_ca_topic_score_codex":0.00031358717,"about_ca_topic_score_gemma":0.00067019305,"teacher_disagreement_score":0.004277861,"about_ca_system_score_codex":0.00035664308,"about_ca_system_score_gemma":0.0005396741,"threshold_uncertainty_score":0.01799506},"labels":[],"label_agreement":null},{"id":"W4409504657","doi":"10.1002/cpdd.1534","title":"A Phase 1C, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DM199 Administered Intravenously with a Polyvinyl Chloride Bag in Adult Healthy Subjects and Adults Recently Taking Angiotensin‐Converting Enzyme Inhibitors","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Calgary","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Adverse effect; Dosing; Context (archaeology); Anesthesia; Pharmacology; Internal medicine","score_opus":0.06909627066100327,"score_gpt":0.42693431326928105,"score_spread":0.3578380426082778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409504657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652666,0.0005640771,0.0006466988,0.000090863265,0.000034339268,0.001331339,0.00027293773,0.000029712462,0.0005034263],"genre_scores_gemma":[0.992778,0.0008804533,0.0018492822,0.00047378003,0.0001261815,0.0016416061,0.00057557196,0.000014086735,0.0016610717],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996977,0.0001353823,0.000018369117,0.000057392575,0.00004929765,0.00004185709],"domain_scores_gemma":[0.9995338,0.000107341526,0.00011081526,0.000039241044,0.000043722473,0.00016512086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093078415,0.0010038887,0.0013144221,0.00031780405,0.0003633687,0.00045622542,0.0004649486,0.0008224314,0.0020177632],"category_scores_gemma":[0.00077810156,0.00041417594,0.00053593505,0.00021554521,0.00054313,0.00057713327,0.00018745285,0.0015521441,0.00038869554],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59402555,0.14716135,0.0077153975,0.0007042124,0.0009903762,0.00039033173,0.0003836712,0.0009707535,0.15925051,0.00023006412,0.0015511169,0.08662672],"study_design_scores_gemma":[0.15534964,0.822594,0.013726309,0.000011478428,0.00022621732,0.00017152847,0.00004296907,0.0006225861,0.0058383374,0.00006987998,0.0013259182,0.000021070584],"about_ca_topic_score_codex":0.00054014183,"about_ca_topic_score_gemma":0.0012665247,"teacher_disagreement_score":0.0020177632,"about_ca_system_score_codex":0.00036138535,"about_ca_system_score_gemma":0.0007277989,"threshold_uncertainty_score":0.006750107},"labels":[],"label_agreement":null},{"id":"W4409765779","doi":"10.1002/cpdd.1540","title":"Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"NS5A; Medicine; Pharmacology; Drug; Adverse effect; Hepatitis C virus; NS5B; Combination therapy; Chronic hepatitis; Hepacivirus; Virus; Virology","score_opus":0.217051315865395,"score_gpt":0.6195449109795277,"score_spread":0.4024935951141327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409765779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763477,0.0007827794,0.00036614554,0.000056389636,0.000030511796,0.0005756901,0.00024155965,0.000023337783,0.0002887514],"genre_scores_gemma":[0.99610597,0.0005340459,0.0010972029,0.00019430253,0.00007341938,0.00061407144,0.00053421425,0.000015688967,0.0008310874],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99827266,0.00097571634,0.000072928204,0.00027765014,0.00025318502,0.00014774983],"domain_scores_gemma":[0.99844617,0.0003795788,0.00031114003,0.000108781234,0.0002163699,0.0005379854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003554554,0.0014510329,0.0020859751,0.00029451033,0.00049949577,0.00048473632,0.00055843976,0.0015499627,0.0017732582],"category_scores_gemma":[0.0025625594,0.0005665408,0.0013560278,0.000297301,0.0005927794,0.0006920989,0.00034986777,0.00155213,0.00048734376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6466389,0.08613229,0.04092906,0.00081721874,0.0028762287,0.0008038969,0.00063776475,0.0014007608,0.14078853,0.00007714154,0.00081476744,0.078083515],"study_design_scores_gemma":[0.035072345,0.88858014,0.06100277,0.000014891922,0.001199118,0.00051121396,0.00010666702,0.0012322819,0.010704137,0.000053893044,0.0014748434,0.00004772956],"about_ca_topic_score_codex":0.0005938338,"about_ca_topic_score_gemma":0.0008945969,"teacher_disagreement_score":0.003554554,"about_ca_system_score_codex":0.00040748238,"about_ca_system_score_gemma":0.0006366859,"threshold_uncertainty_score":0.01879847},"labels":[],"label_agreement":null},{"id":"W4409956934","doi":"10.1002/cpdd.1538","title":"A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare","keywords":"Medicine; Tolerability; Dosing; Pharmacokinetics; Adverse effect; Pharmacology; Regimen; Internal medicine","score_opus":0.0388030569631078,"score_gpt":0.4428926940845356,"score_spread":0.40408963712142776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409956934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837399,0.0017737619,0.0012002521,0.0003276822,0.00028444827,0.009929835,0.0011900021,0.000100727586,0.0014533658],"genre_scores_gemma":[0.9789257,0.0017053018,0.003186467,0.00095671625,0.00029943892,0.010940291,0.0012250283,0.00003932934,0.0027216857],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991352,0.00049695635,0.000041837808,0.00015822872,0.000074062846,0.000093760646],"domain_scores_gemma":[0.99867463,0.0004608831,0.00031136442,0.000103867504,0.00011621875,0.0003331462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023419242,0.0015055098,0.0020757467,0.00030515512,0.00045588246,0.00082192064,0.00079117256,0.0014515118,0.0056095603],"category_scores_gemma":[0.0025233747,0.00085831847,0.0010784854,0.0003538867,0.0009167394,0.0009659777,0.00032352807,0.0022829096,0.0007189377],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9571148,0.022533994,0.000942263,0.00042123528,0.00058111013,0.00005343845,0.000066996356,0.00033832298,0.0052905707,0.00010096312,0.00079770165,0.011758608],"study_design_scores_gemma":[0.7964044,0.19897315,0.0020115466,0.000022234535,0.00036487263,0.000047914833,0.000023697585,0.0005912411,0.0006332565,0.00013433819,0.00077819644,0.000015235109],"about_ca_topic_score_codex":0.0007019071,"about_ca_topic_score_gemma":0.0020162007,"teacher_disagreement_score":0.0056095603,"about_ca_system_score_codex":0.0006946437,"about_ca_system_score_gemma":0.0017987527,"threshold_uncertainty_score":0.018765867},"labels":[],"label_agreement":null},{"id":"W4413114117","doi":"10.1002/cpdd.1583","title":"Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Coronavirus disease 2019 (COVID-19); Pharmacokinetics; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Monoclonal antibody; 2019-20 coronavirus outbreak; Pharmacology; Antibody; Immunology; Adverse effect; Internal medicine; Infectious disease (medical specialty); Outbreak; Disease","score_opus":0.05256922252441759,"score_gpt":0.4732816387254207,"score_spread":0.4207124162010031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413114117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99906343,0.0004978224,0.00008415202,0.00002965502,0.0000058597034,0.00006830519,0.0000634519,0.0000059151425,0.0001814516],"genre_scores_gemma":[0.9992052,0.0002542259,0.00013327708,0.00008480126,0.000022514456,0.00005997377,0.00008181791,0.0000013957983,0.0001568644],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996228,0.00015604067,0.000024110443,0.00006072774,0.00008240994,0.000053804466],"domain_scores_gemma":[0.9996803,0.0000643652,0.00011417619,0.000017070506,0.000039555744,0.00008453137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009935792,0.0005009305,0.0006625095,0.00020772776,0.0002856459,0.00023360355,0.00018883489,0.00047253046,0.00080605055],"category_scores_gemma":[0.00076043536,0.0002741453,0.0005232637,0.00019228285,0.0003623677,0.00027508603,0.00014892551,0.00043748724,0.00015229084],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31378207,0.012783757,0.20680505,0.0012800089,0.002041908,0.0010645537,0.0013641036,0.0019191952,0.21808097,0.00016932849,0.0016580201,0.23905109],"study_design_scores_gemma":[0.03509086,0.36258763,0.57906693,0.00003985972,0.00168971,0.00076115376,0.00027796015,0.002130089,0.016194798,0.00009886284,0.0019943435,0.00006773244],"about_ca_topic_score_codex":0.0017472269,"about_ca_topic_score_gemma":0.0023592252,"teacher_disagreement_score":0.0017472269,"about_ca_system_score_codex":0.00040127538,"about_ca_system_score_gemma":0.00045200792,"threshold_uncertainty_score":0.0052546263},"labels":[],"label_agreement":null},{"id":"W4413419348","doi":"10.1002/cpdd.1601","title":"Pharmacokinetics and Pharmacodynamics of Faldaprevir Following Multiple Oral Rising Doses in Healthy Volunteers and Subjects with Gilbert's Syndrome","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Pharmacodynamics; Dosing; Placebo; Pharmacology; Gastroenterology; Adverse effect; Internal medicine","score_opus":0.01964009221475031,"score_gpt":0.3547409551100993,"score_spread":0.33510086289534896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413419348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993311,0.00036504626,0.00008938087,0.000011589451,0.0000058332466,0.000032426018,0.000042029988,0.000011047548,0.00011158286],"genre_scores_gemma":[0.99945444,0.000099265664,0.00012093454,0.00005300792,0.000014424838,0.00003552839,0.00008951944,0.0000021564877,0.00013086983],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967945,0.00016754525,0.000016950285,0.000048871807,0.000042019103,0.0000451752],"domain_scores_gemma":[0.99957067,0.00012893048,0.00008914713,0.000028828179,0.000034409586,0.0001480166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000800471,0.00051114993,0.00089881587,0.0002445539,0.0002509376,0.000324174,0.00013314778,0.0005912021,0.0006947211],"category_scores_gemma":[0.0008889579,0.00026116992,0.00034620924,0.00017313738,0.00033045723,0.0003022498,0.00016154457,0.00051878614,0.00017293196],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4155517,0.011467463,0.27713346,0.00041053974,0.00090878585,0.0012318982,0.0013278155,0.0013734812,0.20632052,0.00014740454,0.0009566939,0.08317027],"study_design_scores_gemma":[0.010814689,0.33642834,0.63221806,0.000027318481,0.0007370281,0.0012014683,0.0004223987,0.0024125774,0.014354253,0.000134015,0.0011958202,0.000053940075],"about_ca_topic_score_codex":0.00063935254,"about_ca_topic_score_gemma":0.0005966807,"teacher_disagreement_score":0.00089881587,"about_ca_system_score_codex":0.00018636201,"about_ca_system_score_gemma":0.0001761205,"threshold_uncertainty_score":0.0042333603},"labels":[],"label_agreement":null},{"id":"W4413419631","doi":"10.1002/cpdd.1580","title":"Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Mental Health & Substance Use Services","funders":"H. Lundbeck A/S; Otsuka Pharmaceutical","keywords":"Aripiprazole; Medicine; Bipolar I disorder; Bipolar disorder; Schizophrenia (object-oriented programming); Internal medicine; Mood; Population; Hazard ratio; Mood disorders; Psychiatry; Confidence interval","score_opus":0.01852491266471569,"score_gpt":0.35802027590335916,"score_spread":0.3394953632386435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413419631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413246,0.00089364796,0.0026905169,0.00022685189,0.000026586767,0.00027657824,0.0010426762,0.000081372425,0.0006293724],"genre_scores_gemma":[0.9971232,0.00019227913,0.0012570411,0.00010078536,0.000015385902,0.00016895037,0.00074565737,0.000015529129,0.00038136297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960007,0.0028352248,0.00020383076,0.0005372451,0.00024246279,0.00018046233],"domain_scores_gemma":[0.9908902,0.0064932154,0.0013435392,0.0006505658,0.00031323405,0.0003091918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009313581,0.0006308414,0.0016597023,0.00044675783,0.00024347602,0.0008472387,0.00068719266,0.0009437834,0.0033254607],"category_scores_gemma":[0.013564326,0.0005882891,0.0047268663,0.0004113641,0.00024359046,0.00061296776,0.00052706955,0.001986558,0.00045031324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34401616,0.005958415,0.4961477,0.0012100436,0.021164669,0.0007272274,0.0008193641,0.0511329,0.009902915,0.00095473154,0.0030120995,0.064953886],"study_design_scores_gemma":[0.017916553,0.071578205,0.63777953,0.00015038394,0.011733029,0.0008872361,0.00041363022,0.24966748,0.0032136843,0.0025565608,0.0038754693,0.00022841174],"about_ca_topic_score_codex":0.0025219976,"about_ca_topic_score_gemma":0.0023166146,"teacher_disagreement_score":0.009313581,"about_ca_system_score_codex":0.0010158791,"about_ca_system_score_gemma":0.0008771013,"threshold_uncertainty_score":0.04925555},"labels":[],"label_agreement":null},{"id":"W4414018844","doi":"10.1002/cpdd.1586","title":"Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"AstraZeneca","keywords":"Pharmacokinetics; Medicine; Placebo; Adverse effect; Internal medicine; Randomized controlled trial; Gastroenterology; Pharmacology; Pathology","score_opus":0.04614544387618751,"score_gpt":0.4838551436213657,"score_spread":0.4377096997451782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414018844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975151,0.0014244611,0.00027785564,0.000103111866,0.000021984666,0.00026903482,0.0000794709,0.000019423578,0.0002895771],"genre_scores_gemma":[0.99675,0.00089137984,0.00075306714,0.00027317106,0.000061871426,0.00041100662,0.00019238744,0.000007878193,0.00065920263],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99940205,0.00033109137,0.0000307137,0.00008530599,0.00007882324,0.0000719558],"domain_scores_gemma":[0.9994554,0.000088552566,0.00019952584,0.00004399098,0.00004579921,0.00016670291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002773614,0.0008466355,0.0013110646,0.00038173638,0.00032345872,0.00049000676,0.00053576776,0.000744035,0.0017319814],"category_scores_gemma":[0.00085442746,0.00061112765,0.0011679989,0.0003381446,0.00085158955,0.0006864609,0.00027048175,0.0010615137,0.00020633294],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71553916,0.024409045,0.028674737,0.0010173062,0.00258603,0.00027352772,0.0005725958,0.001570951,0.09236594,0.00035629177,0.0015490623,0.13108541],"study_design_scores_gemma":[0.43255216,0.4601281,0.08510461,0.000049220165,0.0023881386,0.00029834852,0.0001163302,0.0030142553,0.012994331,0.00018533895,0.0030866016,0.000082647326],"about_ca_topic_score_codex":0.0014413923,"about_ca_topic_score_gemma":0.00260017,"teacher_disagreement_score":0.002773614,"about_ca_system_score_codex":0.00087427476,"about_ca_system_score_gemma":0.0016359206,"threshold_uncertainty_score":0.014668465},"labels":[],"label_agreement":null},{"id":"W4415846907","doi":"10.1002/cpdd.1623","title":"What Does an Editor Do in 2025?","year":2025,"lang":"en","type":"editorial","venue":"Clinical Pharmacology in Drug Development","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Publishing; Conversation; Context (archaeology); Clinical trial; Task (project management); Alternative medicine; Clinical pharmacology; Clinical Practice","score_opus":0.30004322525617194,"score_gpt":0.6214337519721888,"score_spread":0.3213905267160168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415846907","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002470765,0.0047018216,0.0006088893,0.25259566,0.73658377,0.00006801223,0.00011781668,0.0002851523,0.0047917753],"genre_scores_gemma":[0.005306743,0.013599432,0.002884343,0.25331596,0.6763605,0.00024679035,0.00029040017,0.0005203848,0.04747557],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9601798,0.008481527,0.0059623457,0.0038476381,0.019096714,0.0024319827],"domain_scores_gemma":[0.82129717,0.024528243,0.01442996,0.006367128,0.08484605,0.048531447],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.041010175,0.002164569,0.002411419,0.004408901,0.005726732,0.02916449,0.004147687,0.01662734,0.040098745],"category_scores_gemma":[0.1655965,0.0011346089,0.002421863,0.002164804,0.004019795,0.016875993,0.0034441315,0.014635502,0.037614454],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058435962,0.000029837887,0.00038287535,0.00037417284,0.000017003322,0.00034416857,0.0001855107,0.000038185666,0.00018189986,0.0012745659,0.97353137,0.02358218],"study_design_scores_gemma":[0.00003435913,0.00005633841,0.000425086,0.00069341087,0.000022798533,0.0005565542,0.00081957557,0.00012930213,0.00026073033,0.0026498784,0.9943018,0.0000502481],"about_ca_topic_score_codex":0.001295098,"about_ca_topic_score_gemma":0.0033800355,"teacher_disagreement_score":0.9589898,"about_ca_system_score_codex":0.0045578983,"about_ca_system_score_gemma":0.016227875,"threshold_uncertainty_score":0.21688509},"labels":[],"label_agreement":null}]}